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SUMMARY 
Hypoxia is a well-studied prototype and a paradigm of responses that involve the organism as a 
whole with different consequences on health and disease. Prolonged generalized hypoxia is the 
cause of hypoxic pulmonary arterial hypertension (PAH). Conversely hypoxia can also be a 
consequence during uncontrolled growth of tumors with aberrant blood vessels and thus an 
insufficient oxygen supply. In this work, hypoxia was treated from two points of view, as the 
cause in hypoxic PAH or as the consequence of cancer in clear cell renal cell carcinoma (ccRCC). 
Hypoxic conditions stimulate pulmonary vasoconstriction and vascular remodeling, both 
pathognomonic changes in PAH. The secreted protein thrombospondin-1 (TSP1) promotes PAH, 
but it is largely unknown how hypoxia regulates TSP1 in the lung and whether this contributes to 
pathological events in PAH. Using a murine model of constitutive hypoxia, gene silencing and 
luciferase reporter experiments in cells, we found that hypoxia induced pulmonary TSP1 in a 
HIF2α-dependent manner. Additionally, we found that TSP1 induced migration in pulmonary 
fibroblasts and PASMC, and increased permeability in PAEC through effects on the cell-matrix 
and cell-cell interactions. In fibroblasts, TSP1 induced differentiation into a SMC-like phenotype, 
while in PASMC, TSP1 seems to have a role in the regulation of the potassium channel Kv1.5. 
In addition, we found in end-stage PAH patients, both TSP1 and HIF2α protein expression 
increased in pulmonary arteries compared to non-PAH controls. This provides genetic evidence 
that HIF2α-induced TSP1 contributes to vascular response and remodeling during PAH.  
VCAM-1 is an adhesion molecule assigned to the activated endothelium mediating immune cells 
adhesion and extravasation. However, its expression in renal carcinomas inversely correlates with 
tumor malignancy. Our studies in ccRCC demonstrated that loss of VHL, hypoxia or PHD 
inactivation decreased VCAM-1 levels through a transcriptional mechanism that was independent 
of the hypoxia-induced transcription factor HIF and dependent on the NF-κB signaling pathway. 
VCAM-1 decreased levels in ccRCC might be relevant to tumor cell immune evasion since this 
molecule elicited immune cell binding specifically mediated by its interaction with the α4β1 
integrin expressed in the immune cells. Furthermore, this interaction made ccRCC cells more 
sensitive to the cytotoxic effects mediated by activated monocytic cells. Remarkably, in ccRCC 
human samples with VHL non-missense mutations we observed a negative correlation between 
VCAM-1 levels and ccRCC stage and microvascular invasion pointing out the clinical value of 
VCAM-1 levels as a marker of ccRCC progression.
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RESUMEN 
La hipoxia es un proceso bien estudiado y un paradigma de respuestas que involucran al 
organismo como un todo con diferentes consecuencias sobre la salud y la enfermedad. La hipoxia 
generalizada prolongada es la causa de la hipertensión arterial pulmonar (HAP) inducida por 
hipoxia. Por el contrario, la hipoxia también puede ser una consecuencia durante el crecimiento 
descontrolado de tumores con vasos sanguíneos aberrantes y, por tanto, un suministro insuficiente 
de oxígeno. En este trabajo, la hipoxia se ha tratado desde dos puntos de vista, como causa en 
HAP hipóxica o como consecuencia en el carcinoma renal de célula clara (ccRCC). 
La hipoxia estimula la vasoconstricción pulmonar y el remodelado vascular, cambios 
patognomónicos en la HAP. La proteína secretada trombospondina-1 (TSP1) promueve la HAP, 
pero se desconoce cómo la hipoxia regula su expresión en pulmón y si esto contribuye a los 
eventos patológicos en la HAP. Usando un modelo murino de hipoxia constitutiva, silenciamiento 
génico y experimentos reporteros, encontramos que la hipoxia inducía TSP1 en pulmón de manera 
dependiente de HIF2α. Además, se encontró que TSP1 inducía la migración de fibroblastos 
pulmonares y PASMC, y aumentaba la permeabilidad en PAEC, a través de efectos sobre las 
interacciones célula-matriz y célula-célula. En los fibroblastos, TSP1 indujo la diferenciación a 
un fenotipo de tipo SMC y en PASMC TSP1 parece tener un papel en la regulación del canal de 
potasio Kv1.5. Además, en pacientes en estado terminal de HAP se encontraron altos niveles de 
TSP1 y HIF2α comparados con controles sanos. Estos resultados proporcionan evidencias 
genéticas de que la TSP1 inducida por hipoxia contribuye a la respuesta vascular y al remodelado 
durante la HAP. 
VCAM-1 es una molécula de adhesión asignada al endotelio activado que media la adhesión y la 
extravasación de las células inmunes. Sin embargo, su expresión en carcinoma renal se 
correlaciona inversamente con tumores malignos. Nuestros estudios en ccRCC demostraron que 
la pérdida de VHL, la hipoxia o la inactivación de las PHDs disminuían los niveles de VCAM-1 
a través de un mecanismo de transcripción que era independiente del factor de transcripción HIF 
y dependiente de la vía de señalización NF-κB. Los niveles disminuidos de VCAM-1 en ccRCC 
podrían ser relevantes para la evasión inmune de células tumorales, ya que la interacción de esta 
molécula con su receptor, la integrina α4β1 expresada en células inmunes, provocó la unión de 
las células inmunes con las células ccRCC. Además, esta interacción hizo que las células ccRCC 
fueran más sensibles a los efectos citotóxicos mediados por células monocíticas activadas. Es 
destacable que en muestras humanas de ccRCC con mutaciones sin sentido en vhl se observó una 
correlación negativa entre los niveles de VCAM-1 y el estadio de ccRCC y la invasión 
microvascular señalando el valor clínico de los niveles de VCAM-1 como marcador de progresión 
de ccRCC. 
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INTRODUCTION 
HYPOXIA, GENERAL LINES AND MECHANISM OF CONTROL 
The term hypoxia is defined as a deficiency in the amount of oxygen that reaches the tissues of 
the body. It differs from hypoxemia, which means an inadequate amount of oxygen traveling in 
the blood. Hypoxia may affect the whole body, when is generalized, or a specific organ or tissue, 
then is considered tissue hypoxia or local hypoxia. Generalized hypoxia may occur under different 
conditions, these including high altitude, when people breathe air with displaced oxygen due to a 
chemical process or treatment, due to respiratory problems, deficiencies in blood flow or 
insufficient hemoglobin (known as anemia), all of them leading to a decrease in the partial 
pressure of oxygen and hypoxemia. Conversely, local hypoxia occurs when a tissue is not 
properly perfused, generally due to blood irrigation problems. The most common cases are 
hemorrhages or vascular obstructions, such cerebral ischemia, myocardial stroke or in 
inflammatory foci. In addition, local hypoxia is present in the core of solid tumors, being this 
considered a hallmark of tumor progression (Figure 1). Hypoxia can also be acute or chronic, 
with acute meaning a rapid onset, and chronic meaning that hypoxia has been ongoing for long 
time. Although hypoxia is considered a physiopathological event, low oxygen levels are a 
common feature under physiological conditions such as embryonic development [1], physical 
exercise [2] or in specific microenvironments such as the stem cell niche [3]. 
In mammals, the oxygen passively diffuses from the breathed air to the arterial blood. This 
process takes place in the lung alveoli, the minimal structure for gases interchange, according to 
a pressure gradient. Once in the blood, oxygen is transported by the hemoglobin in red blood cells 
and delivered to the tissues, where it reaches the cells by passive diffusion. Cells use the oxygen 
to generate energy in form of adenosine triphosphate (ATP) by the oxidative phosphorylation in 
the mitochondria. During the aerobic respiration, the mitochondria generates ATP by oxidizing 
glucose products, pyruvate and NADH. When oxygen is limited, the glycolytic products are 
metabolized by anaerobic fermentation, an independent and less efficient mitochondrial process. 
Furthermore, during hypoxia, hydrogen is shifted to pyruvic acid producing lactic acid, switching 
the cell to an anaerobic metabolism. This response is mainly mediated by the hypoxic inducible 
factors (HIFs), which also regulates several cellular mechanisms to hypoxic adaptation as 
angiogenesis in order to improve blood flow and oxygen support (Figure 1). 
Systemic Response to Hypoxia 
As oxygen is absolutely essential for complex organisms, they have developed different 
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physiological responses that permit adaptation to a hypoxic environment. The Carotid body 
through the release of neurotransmitters increases respiration and cardiac rate. The medulla 
oblongata in the brain measures the partial pressure of CO2 and H+ and integrates signals from 
carotid body and other parts of the body increasing respiration and cardiac rate. The pulmonary 
arteries suffer a vasoconstriction to redirect blood flow to alveoli with higher oxygen content. 
Conversely a systemic vasodilatation occurs to help blood flow to reach the whole body. In 
addition, the kidneys response increasing erythropoietin (EPO) levels (Figure 1). 
 
  Figure 1: Scheme of systemic and local responses to hypoxia. 
 
Carotid Body Response 
Carotid body (CB) is a small arterial chemoreceptor located at the bifurcation of the carotid artery. 
Its function is to detect changes in blood oxygen levels and activate the respiratory center to allow 
the correct adaptive ventilatory response. The CB is composed of functional units named 
glomeruli, which are clusters of cells separated by a profuse network of small capillaries and 
connective tissue. It is thought that mitochondria produce reactive oxygen species (ROS) and 
reduced pyridine nucleotides under hypoxia. These molecules lead to cell depolarization, calcium 
entry, and neurotransmitters release, which activate the afferent fibers of the sinus nerve. [4-6]. 
This ion cascade ends releasing dopamine to the next afferent nerve producing an increase in 
respiration and cardiac rate (Figure 1). 
Erythropoietin production   
Erythropoietin (EPO) is produced by interstitial fibroblast in the kidney in close association with 
peritubular capillary and proximal convoluted tubule and in perisinusoidal cells in the liver. While 
liver production predominates in the fetal and perinatal period, kidneys are the main physiologic 
site of EPO synthesis during adulthood. Under hypoxia these organs increase the levels of EPO 
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[7, 8]. The increase on EPO levels contributes to heighten the levels of red blood cells aimed to 
compensate the decrease of oxygen in the tissues [9] (Figure 1). 
Vascular adaptation to hypoxia 
In response to hypoxia most of the vessels of the body have a vasodilatory response aimed to 
increase oxygen supply. Conversely, the lungs response to hypoxia with vasoconstriction, also 
called hypoxic pulmonary vasoconstriction (HPV) (Figure 1). It is thought that the first signals 
for general hypoxic vasodilation and hypoxic pulmonary vasoconstriction could be the same, and 
that their effect depends on the cellular type and localization. Nevertheless, the effects are 
completely opposed [10, 11]. Vasodilation is the process of blood vessels widening which 
increases perfusion by decreasing vascular resistance. It is leaded by the relaxation of the smooth 
muscle cells (SMC) within the tunica media of the vessels walls of arteries, arterioles and large 
veins. The vascular tone depends on the intracellular calcium ion concentration, which is closely 
linked with phosphorylation of the light chain of the contractile protein myosin. Therefore, 
vasodilation occurs after lowering intracellular calcium concentration or by dephosphorylation of 
myosin in SMC [12, 13]. Although hypoxic vasodilation very first events are endothelium-
independent [14], endothelial cells regulate vascular tone in prolonged hypoxia as well as in 
physiological conditions. There are two main endothelial-dependent vasodilation pathways: via 
cGMP and via cAMP. This two molecules can modulate several targets including multiple 
calcium, potassium and ATPase channels, myosin light-chain kinase (MLCK) or Rho kinase, 
among others. The response varies between different cell types and species. One main example 
of each pathway is described below: 
1. Via cGMP: E.g. Nitric oxide (NO) activates soluble guanylate cyclase, which catalyzes the 
formation of cyclic guanosine monophosphate (cGMP), this activates protein kinase G (PKG) 
causing the reuptake of calcium and the opening of calcium-activated potassium channels (Kca) 
as big potassium channel (BKca). The opening of Kca channels causes membrane 
hyperpolarization and the close of voltage-dependent calcium channels (VDCC) [15, 16], which 
in turn decreases the intracellular calcium concentration [17]. In these conditions, MLCK can no 
longer phosphorylate the myosin molecule, thereby stopping the crossbridge cycle and leading to 
relaxation of the SMC. 
2. Via cAMP: Direct modulation of MLC phosphorylation. Some vasodilators as prostaglandins 
(e. g. PGI2) trigger the activation of adenylate cyclase, increasing cyclic adenosine 
monophosphate (cAMP), which activates protein kinase A (PKA) that subsequently inhibits 
MLCK by phosphorylation [18]. Dephosphorylated myosin light chain (MLC) cannot continue 
the crossbridge cycle and therefore SMC falls into relaxation [19, 20].  
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Hypoxic pulmonary vasoconstriction (HPV), also known as the von Euler–Liljestrand 
mechanism, is a physiological phenomenon that happens in pulmonary arteries under hypoxia. 
HPV achieves to redirect blood flow to alveoli with more oxygen, improving gaseous exchange. 
HPV is activated at a partial pressure of oxygen (PO2) of 100 mmHg (13.3 kPa), which is 
equivalent to an altitude of approximately 3700 meters. Pulmonary arterial smooth muscle cells 
(PASMC) contract in response to hypoxia at a PO2 of 25–50 mmHg (3.33–6.66 kPa) [21] in an 
endothelium-independent manner [22]. Intracellular calcium increases by the influx of 
extracellular calcium and the release of intracellularly stored calcium from the endoplasmic 
reticulum and mitochondria [23]. There are multiple components generally accepted in the 
calcium enhancement mechanism; L-type calcium channels, potassium voltage dependent 
channels (Kv), non-selective cationic channels (NSCC) (e.g. TRP channels) and Rho-kinase 
involved that could be activated sequentially or in parallel during HPV [23-25]. When hypoxia is 
maintained for long periods (hours, days or months), as it occurs at high altitude or during 
respiratory diseases, these including chronic obstructive pulmonary disease (COPD), sleep apnea, 
fibrosis, or failure of ventilation due to neurological diseases, HPV produces vascular remodeling 
processes with subsequent pulmonary arterial hypertension and finally right heart hypertrophy 
and cor pulmonale [24]. 
Cellular response to hypoxia: Oxygen sensing machinery 
Oxygen supply is essential for aerobic organisms to generate energy. In order to overcome the 
insufficient oxygen availability, mammals have also developed cellular adaptive responses to 
match oxygen supply with metabolic, bioenergetics, and redox demands. Cells may stop cell 
cycle, decrease energy consumption and generate survival and proangiogenic factors. All these 
actions are orchestrated by cellular pathways like mammalian target of rapamycin (mTOR), 
unfolded protein response or gene regulation by HIFs, which were initially described as regulators 
of EPO production and nowadays they are considered the most important genetic factors in 
response to hypoxia. 
Hypoxia inducible factors 
HIFs are a family α/β-heterodimeric transcription factors that regulate the expression of hundreds 
of genes in a tissue context-dependent manner. These transcription factors are heterodimers 
composed of a constitutively expressed beta subunit (HIFβ), also known as aryl receptor nuclear 
translocator (ARNT) and an oxygen-regulated 𝛼 subunit (HIF𝛼). In mammals, there are three 
different alpha isoforms of HIF𝛼: HIF1α /MOP1, HIF2𝛼/EPAS (endothelial PAS)/MOP2 and 
HIF3𝛼 (IPAS), being HIF1𝛼 and 2𝛼 the most studied isoforms. Both subunits belong to the basic-
helix-loop-helix (bHLH) family of transcription factors containing a Pax/Aryl hydrocarbon 
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receptor/Sim (PAS) domain [26-29]. HIF1α and HIF2α subunits also carry N- and C-terminal 
transactivation domains (N-TAD and C-TAD) that are required for the activation of HIF target 
genes. The C-TAD domain interacts with coactivators such as CBP/p300 to activate gene 
transcription [30]. An oxygen-dependent degradation domains (ODDD) within these alpha 
subunits confer oxygen-regulated turnover as it contains the key asparagine (N) and proline (P) 
residues targeted for hydroxylation in normoxic conditions [31-35]. HIFα subunits 
heterodimerize with HIFβ by their bHLH and PAS domains [36]. Transcriptionally active HIF 
heterodimers get into the nucleus and bind to hypoxia response elements (HREs) in the chromatin, 
(Figure 2). These HRE are DNA consensus sequences containing a conserved core with 
G/ACGTG, which is similar to the Enhancer box (E-box) to induce adaptive hypoxic genes [37]. 
Comparatively much less is known about HIF3α, although is also regulated by oxygen [38]. 
HIF3α is considered a negative regulator of hypoxia-inducible genes [39].  
 
Figure 2: Simplified scheme of signaling networks in the regulation of HIF. Classical and some 
alternative regulations of HIF under normoxia or hypoxia are represented.  
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Isoform-specific genetic regulation of HIFα 
Despite HIF1α and HIF2α recognize the same HRE sequences, they can induce equal or 
differential gene expression in a context-dependent manner. Different cell type, severity, 
association with regulatory proteins, duration and variety of stimulation as well as the presence 
of functional VHL could shift the transcriptional regulation between HIF1α and HIF2α [37, 40, 
41]. HIF1α is ubiquitously expressed while HIF2α is predominantly expressed in the lung, 
endothelium, and carotid body [42-44]. Several pieces of evidence support a temporal 
organization of HIF1α and HIF2α-dependent responses. Under acute hypoxia transactivation of 
target genes is primarily mediated by HIF1α, while during longer hypoxic insults HIF2α becomes 
more relevant [40, 45]. HIF1α is the main activator of glycolytic genes, allowing cells to adapt to 
low oxygen by switching the oxidative phosphorylation to anaerobic glycolysis (also known as 
Warburg Effect) [46-50]. At the same time, HIF1α down-regulates oxidative phosphorylation 
through a range of actions on mitochondrial metabolism and biogenesis. For instance, the activity 
of mitochondrial complex I is inhibited by HIF1α-mediated activation of NDUFA4L2 [51]. 
Meanwhile, HIF2α plays preferably a role in the expression of genes involved in pluripotent stem 
cell maintenance [52, 53], and angiogenesis [54]. Therefore, the effects of HIFα are complex and 
involves the activation of several adaptive pathways that may in turn require the expression of a 
specific set of genes [45, 55-57] (Figure 3).  
 
Hypoxic inducible factors regulation 
As the main orchestrators in the response to hypoxia, the expression of HIFs is tightly regulated. 
In normoxic conditions, two proline residues found at aminoacid positions 402 and 564 in HIF1α 
and, 405 and 531 in HIF2α, located within the oxygen-dependent degradation domain (ODDD) 
[58, 59] are hydroxylated by a family of oxygen–dependent dioxygenases termed PHD (for prolyl 
hydroxylase domain containing proteins) [60, 61]. Prolyl hydroxylation promotes HIFα 
interaction with the von Hippel-Lindau protein (VHL) [62], which promotes polyubiquitination 
and thereby targeting the HIFα protein for degradation by the 26S subunit of the proteasome [63, 
64]. Under hypoxia, PHD activity is significantly decreased, HIFα is not degraded and therefore 
heterodimerizes with HIFβ promoting the expression of hypoxic genes [37, 39, 57, 65] (Figure 
3). 
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Figure 3: HIF target genes in several adaptive pathways. Figure modified from Dengler et al 2014 [37]. 
Von Hippel Lindau protein  
VHL is a tumor suppression protein encoded by the gen vhl. It was described in 1894 by Treacher 
Collins, although its name was given by the german ophthalmologist Eugene von Hippel and the 
Swedish pathologist Arvid Lindau, who studied retinal and cerebellar disease lesions one decade 
later [66]. Two isoforms with functional activity have been reported, with 213 or 160 aminoacids 
length each, and molecular weights of 30 and 19 kDa respectively [67]. Mutations in the germline 
of the vhl gene are the basis of familial Von Hippel Lindau disease, a dominantly inherited cancer 
syndrome predisposing to a variety of tumors as kidney, pancreas, brain or eye. One mutation 
alone is not sufficient to alter VHL function, but when the second allele of vhl is mutated it may 
promote carcinomas. Germline mutations of the VHL gene are now identified in more than 95% 
of the patients with clinical manifestations of the disease [68]. The largest group of mutations 
accounting for about 50% of cases is represented by missense mutations. In about 30% of the 
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cases, deletions that remove one or more exons of VHL are observed and usually arise from 
Arthrobacter luteus (Alu) restriction endonuclease-mediated recombination [69]. Remaining 
mutations consist in nonsense mutations, splicing sites mutations, microinsertions or 
microdeletions leading to truncated proteins [62]. Therefore, nature of the mutation in the vhl 
gene leads to phenotypic manifestations in the pattern of cancer that develops. Nonsense 
mutations or deletion have been linked to type 1 disease, which is the most frequent form of all 
and is mostly characterized by the development of haemangioblastomas (HGB) and renal cell 
carcinomas (RCC), with a low risk of pheochromocytomas (PCC). Type 2 VHL has been linked 
to missense mutations and it has been further subdivided based on the risk to develop RCC. Type 
2A families are affected by the presence of HGB and PCC with a low risk of RCC; type 2B by 
the presence of HGB, PCC and high risk of RCC; and type 2C only by the presence of PCC [70]. 
Patients with type 3 disease are affected by Chuvash polycythaemia, a heritable disease linked to 
homozygous or compound heterozygous VHL mutations [71]. These patients are characterized 
by elevated hematocrit and increased serum levels of erythropoietin and vascular endothelial 
growth factor (VEGF), but do not develop any of the other usual features of VHL disease. In 
types 1, 2A, 2B and 3 the mutant VHL is defective in HIF regulation, while type 2C mutant are 
defective in protein kinase C regulation and fibronectin assembly [62].  
VHL protein is composed by an α domain implicated in the formation of a multi-subunit complex 
and a β domain that mediates substrate recognition. VHL forms part of an ubiquitin-ligase E3 
complex known as the VEC complex, together with Elongin B, Elongin C, Cullin2 (Cul2) and 
Rbx1 (also known as ROC1/Hrt1). Elongin C is in the core of the complex, binding VHL, Cul2 
and Elongin B [72]. Cul2 acts as a bridge associating Rbx1 to Elongin C. VHL interacts with 
Elongin C through amino acids 157-170 in the α domain and with HIF1α through amino acids 
67-117 in the β domain, mutations in these regions are extremely relevant for VHL syndrome 
[73].  This VHL-E3 complex works as polyubiquitination machine, once a protein is ubiquitinated, 
it is degraded by proteasome [72, 74, 75] (Figure 2, right side). Although VHL main role is to 
label proteins for degradation, as HIFα and other targets like MAPK1 [76], in few special cases 
it has been observed that VHL has an opposite role increasing half-life of proteins such as the 
Bcl2-interacting mediator of cell death extra long, (BIMEL) [77], p53 [78] and Jade-1 [79, 80]. 
Moreover, it has been recently published that VHL can protect HIF1α from SART1-mediated 
degradation in clear-cell renal cell carcinoma (ccRCC) [81]. In addition to protein degradation 
and stabilization functions, VHL has been shown to play an important role in the maintenance of 
cell morphology [82, 83] through HIF-dependent or HIF-independent mechanisms [84-86].  
Inactivation of VHL impairs HIFα degradation and this promotes inappropriate activation of 
downstream target genes that directly contribute to tumorigenesis. Consistent with the notion that 
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regulation of HIFα is the key in the tumor suppressor function of VHL, a large proportion of VHL 
mutations-associated diseases have been predicted and demonstrated to significantly impair the 
interaction between VHL and HIF [66, 87, 88]. However, in the absence of VHL, the stabilization 
of HIF is not the unique mechanism to promote tumor growth. VHL is closely involved with the 
regulation of energy and homeostasis during tumor progression, maintenance of the epithelial 
phenotype of renal tubular cells, and regulation of extracellular matrix degradation and 
homeostasis [89-91]. Studies of HIF-independent functions of VHL in cancer have shown that 
VHL expression abolishes the activation of the canonical Nuclear Factor Kappa-light-chain-
enhancer of activated B cells (NF-κB) pathway and the induction of anti-apoptotic genes in those 
cells [92-94]. Cummins et al have demonstrated that VHL interacts with IKKs in a PHD-
dependent manner [95]. Taking into account the multiple loose ends and the increasing 
complexity of NF-κB pathway, the molecular mechanisms underlying VHL-mediated 
suppression of NF-κB need to be more deeply studied.  
Prolyl hydroxylase domain proteins 
PHDs are a family of prolyl hydroxylase domain proteins, which main role is to hydroxylate 
prolines residues. These enzymes require iron, α-ketoglutarate (2-oxoglutarate), ascorbate and 
molecular oxygen for their catalytic activity. There are three isoforms of PHDs: PHD1, PHD2 
and PHD3, also known as HIF𝛼P4Hs (HPHs)3, HIF𝛼P4Hs (HPHs)2 and HIF𝛼P4Hs (HPHs)1 or 
EGLN2, EGLN1 and EGLN3 respectively. Although PHD2 has a dominant role controlling the 
levels of HIF1α [96], all PHD isoforms contribute to the regulation of HIF in a cell-specific way 
[61]. During the prolyl hydroxylation reaction, α-ketoglutarate is oxidatively decarboxylated to 
produce succinate and CO2 i.e. PHDs incorporates one atom of oxygen from dioxygen molecule 
(O2) into the hydroxylated proline and the other into the succinate [97]. Ascorbate (vitamin C) 
recovers active PHD state through the reduction of the inactive iron (III) to the active iron (II) 
[98, 99]. They mainly hydroxylate prolines in LXXLAP protein motifs as in HIFα [58], although, 
they can also hydroxylate prolines in alternative protein motifs [100-102]. 
PHDs also interact with key components of the NFκB pathway. For instance, PHD1 hydroxylates 
IκB kinases (IKKs) under normoxia [95]; PHD2 controls TNF-α effects by positively regulating 
NF-κB signaling [103]; and PHD3 serves as a co-activator of NF-κB signaling activity [104]. 
PHDs also interact with other factors such as the activating transcription factor 4 (ATF4) [105]. 
ATF-4 was shown to interact with PHD3, but not with PHD1 or PHD2. Like HIFα, ATF4 is 
stabilized by PHD inhibitors, hypoxia, and proteasome inhibitors. The interaction was mapped to 
a portion of the zipper II domain, which contains five proline residues, although none are within 
an LXXLAP motif. As well as ATF4, β2-subtype adrenergic receptor (β2AR) is hydroxylated by 
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PHD3 in prolines that are not located in LXXLAP motif. Hydroxylation of proline residues in 
β2AR promotes the binding of pVHL-E3 ligase, and consequently degradation by the proteasoma 
[102]. Because of their oxygen dependence, and the fact that they have a Km value for oxygen 
greater than the concentration of molecular oxygen in tissues [106], which allows the enzymatic 
activity to report on oxygen concentrations along the physiological range, PHDs have been 
proposed to be “oxygen sensors”. However, studies inhibiting components of the electron 
transport chain (ETC) have shown that mitochondria stimulate the production of cellular ROS, 
which inhibit PHD activity and HIFα degradation [107-109]. Therefore, the mitochondria can 
also participate in oxygen sensing, although the notion of mitochondria as “oxygen sensor” is still 
controversial, and many questions remain still unanswered.  
Alternative mechanisms in the regulation of HIF  
Although the Hypoxia/VHL/PHDs axis is considered the canonical pathway in HIF regulation, 
there are a number of alternative mechanisms that can regulate HIF. These mechanisms can 
regulate its transactivation or their interaction with other transcription factors or cofactors. They 
can also affect HIF protein stabilization by post-translational modifications as in the canonical 
pathway or even control HIF abundance through post-transcriptional or transcriptional regulation. 
Alternative post-translational regulations include modifications that affect HIF transactivation 
activity, as that mediated by factor inhibiting HIF1α (FIH1), an asparaginyl hydroxylase that 
hydroxylates the asparagine Asn803 or Asn847 within the C-TADs of HIF1α or HIF2α 
respectively, thereby disrupting the interaction with the coactivator CBP/p300 and the 
transactivation potential of these factors [110, 111]. Acetylation of HIF by the acetyl-transferase 
named arrest-defective-1 (ARD1) or SUMOylation are post-translational modifications that affect 
HIF protein stability [112, 113] (Figure 2, right side). In addition, changes on HIF 
phosphorylation have been shown to regulate both, transactivation and HIFα stability [114-117]. 
Functional analysis revealed that there is an interplay between HIFs and other transcription factors 
that cooperate to fine-tune the expression of HIF target genes [37, 41]. These cofactors include 
members of the p160 family of coactivators [118], the pyruvate kinase M2 isoform (PKM2) [101, 
119], mediator-associated kinase (CDK8) [120] or Sirtuin-6 (SIRT6) [121]. Other stimulus may 
also induce HIF1α mRNA levels through transcriptional mechanisms. For instance, transcription 
factors such NF-κB and Egr1 act upon their respective binding sites on the HIF1α promoter [122, 
123]. HIF transcripts can also be subjected to regulation at the levels of pre-mRNA splicing and 
maturation, as well as mRNA export to the cytoplasm, stability, and translation [124]. Therefore, 
there are many regulatory pathways. Additionally, under normoxic conditions several cytokines 
and growth factors, like IGF2, IL-1β, TNF-α and EGF among others, can affect HIF through post-
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transcriptional mechanisms. The signaling pathways involved in HIF induction by these factors 
include PI3K, MAPK and MEK [125-127]. Moreover, other oncogenes and tumor suppressor 
genes including PTEN, mTOR, Ras, Akt and p53 also regulate HIF activity through different 
mechanisms [128-130], revealing the importance of HIF in tumor growth and development 
(Figure 2). 
HYPOXIA AND DISEASE 
Hypoxia is a well-studied prototype and a paradigm of responses that involve the organism as a 
whole with different consequences on health and disease. Prolonged generalized hypoxia is the 
cause of hypoxic pulmonary arterial hypertension (PAH). Conversely hypoxia can also occur as 
a consequence of numerous pathologies, these including pathologies of the respiratory system 
such as chronic obstructive pulmonary disease (COPD) or pulmonary fibrosis, pathologies 
produced by ischemic processes such as myocardial infarction or cerebral stroke, but also 
uncontrolled growth of tumors causes aberrant blood vessels and thus an insufficient oxygen 
supply. In this thesis, hypoxia will be treated from two points of view, as the cause or as the 
consequence of a pathological process. Although there are many pathological conditions in which 
hypoxia have been involved, we will focus on the role of hypoxia in PAH, and in ccRCC, being 
hypoxia the cause or the consequence of these pathologies. 
Pulmonary Arterial Hypertension 
PAH or just pulmonary hypertension (PH) is characterized by a progressive elevation of 
pulmonary arterial pressure (PAP ≥ 25mmHg at rest) due to changes in the structure and function 
of pulmonary arteries (PA), ultimately producing right ventricular failure and death (Figure 4). 
Initially described by Dr. Ernst von Romberg in 1891 [131]. PAH symptoms include as shortness 
of breath, fatigue, non-productive cough, weakness, angina pectoris, syncope and peripheral 
edema [132]. The World Health Organization (WHO) has classified PH in five groups; the first 
includes idiopathic and hereditable PAH, induced by drugs and toxins or associated with other 
diseases. The other four groups correspond to PAH due to left heart disease; lung disease and/or 
hypoxemia; chronic thromboembolic pulmonary hypertension (CTEPH) and other PA 
obstruction; and PH with unclear and/or multifactorial mechanism [132]. Moreover, the New 
York Heart Association (NYAH) and the WHO classify PH into four functional classes that share 
a similar degree of exercise limitation, symptoms and prognosis. [133-135]. Epidemiologic 
studies report a greater incidence of the disease in females, and depending on the disease 
classification the female-to-male ratio can be as great as 4:1 [136]. PAH class I has a prevalence 
of 15-60 cases per million population and an incidence of 5-10 cases per million per year in 
Europe. In some cases, a genetic mutation has been linked to human disease [137]. Still, in most 
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instances the causative events remain unknown and this likely contributes to the delay in 
therapeutic progress. Elevated pulmonary pressure results from a decrease in arterial lumen 
through the combination of increased contractility of pulmonary arteries, endothelial dysfunction, 
proliferation and remodeling of PA cells, and thrombosis.  
In PAH, vasoconstriction is originated by a decrease in the production of vasodilators/growth 
inhibitors such as NO and PGI2, while there is an increase in the production of 
vasoconstrictor/pro-mitogens such as endothelin-1 (ET-1), thromboxane-2 (TXA2) and serotonin 
or 5-hydroxytryptamine (5-HT) [138, 139]. This miss-regulation of endothelial cells is called 
endothelial dysfunction and may have implications in all the pathologic events of PAH. It is also 
crucial the regulation of K+/Ca2+ channels [140, 141]. Several studies have reported the 
involvement of Kv channels in controlling membrane potential of PASMC and PA tone [142]. It 
has been also described that Kv1.5 has an important role in the development of PAH as a result 
of mutation or downregulation of the channel [143, 144]. Moreover, acute hypoxia causes 
pulmonary vasoconstriction in some degree by inhibiting Kv activity in PASMC [145], caused in 
part by AMPK-mediated phosphorylation and inhibition of Kv1.5 [25]. However, the link 
between long-term hypoxia and the repression of this channel remains poorly understood. 
Remodeling of PA is considered one of the most important hallmarks in PAH. The three main 
cellular types of the PA, endothelial (PAEC) in the tunica intima or endothelium, PASMC in the 
tunica media, and fibroblast (PAFIB) in the tunica adventitia contribute to this process. PAEC 
overgrowth cause neointimal formation, plexiform lesions and endothelial dysfunction [146]. 
PASMC show aberrant proliferation leading to tunica media thickening. They also miss-regulate 
and inhibit the activity of ion channels losing the control of contraction and relaxation. PAFIB in 
turn suffer a process of differentiation to SMC-like phenotype contributing to the thickening of 
the media layer, [147, 148]. They release growth factors and interleukins, generating more 
overgrowth and inflammation [149, 150]. They also exacerbate the synthesis of extracellular 
matrix, releasing huge amounts of collagen, fibronectin and elastin [151]. Moreover, PAEC, 
PASMC and PAFIB can migrate through the arterial layers disrupting arterial functions and 
promoting remodeling [23, 139]. 
Thrombosis is a complex process characterized by the interaction of ECs with both, soluble 
elements (plasma coagulation proteins) and cellular elements of blood such as platelets. In PAH, 
the balance between thrombotic and antithrombotic is lost, generating thrombosis in small arteries 
and increasing arterial pressure. Therefore, thrombosis occurs in PAH by a hypercoagulant 
phenotype characterized by increased levels of plasminogen activator inhibitor-1 (PAI-1), von 
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Willebrand factor, TXA2 and 5-HT, and decreased levels of tissue plasminogen activator (t-PA), 
thrombomodulin, NO and PGI2 [152]. 
 
 
Figure 4: Graphical abstract of cellular events in PAH. Small PAs are progressively narrowed, leading 
to an increase in pulmonary vascular resistance (PVR) and the PA pressures. The progressive increase in 
PVR and pulmonary pressures subsequently lead to reduced cardiac output (CO) and right heart failure. 
RA (right atrium); and RV (right ventricle). Figure modified from Lai et al 2014 [153]. 
 
Studies in animal models and human subjects have identified a number of signaling mechanisms 
that are dysregulated in the setting of PAH including hyperactive vasoconstriction [154] and loss 
of vasodilation in general and NO-mediated vasodilation in particular [155, 156]. Hypoxia 
stimulates pulmonary vasoconstriction and, if chronic, causes hypertrophy of the tunica media of 
PAs [157]. In a feed-forward manner, vascular deterioration due to decreased blood flow through 
the lungs further exacerbates tissue hypoxia [158]. Most responses to hypoxia are mediated 
through the induction of the HIF pathway. Although HIF2α is abundantly expressed in the lung 
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[159], studies in mutant mice suggest that both HIF1α and HIF2α are involved in the hypoxic 
adaptive process in the lung vasculature [160-163].In heterozygous hif1α+/- mice, hypoxia-
induced vascular remodeling is decreased [160]. Likewise, heterozygous hif2α+/- mice did not 
develop pulmonary hypertension following prolonged hypoxia [161]. Furthermore, dysregulation 
of the HIF pathway has been reported to promote pulmonary hypertension both in mouse models 
and human patients with HIF2α mutations [164, 165]. However, the molecular changes triggered 
by HIF are incompletely understood. Now is being appreciated the role of thrombospondin-1 
(TSP1), a matricellular protein reported to be important in the maintenance of vascular 
homeostasis [166, 167], in the development of PAH. It has been shown that hypoxia induces 
vascular cell expression of TSP1 [168] and it has been found high levels of TSP1 in PAH patients 
[169-172]. Nonetheless, it is largely unknown how hypoxia regulates TSP1 in the lung, whether 
this occurs in a HIF-dependent manner, and if this regulation contributes to pulmonary vascular 
dysfunction and PAH. 
Thrombospondin-1 
TSP1 belongs to the family of thrombospondins, a family of highly conserved, oligomeric and 
multi-domain matricellular glycoproteins [173]. These proteins are non-structural proteins 
dynamically expressed and present in the extracellular matrix during specific developmental or 
pathological events. They generally have regulatory roles binding to other extracellular matrix 
proteins, cell surface receptors or signaling proteins [174]. This family consists of 5 members that 
are subdivided into 2 subgroups according to the state of oligomerization and molecular structure 
[173].  TSP1 and TSP2, forms part of the group 1. These two members of the thrombospondin 
family are organized in homotrimers and contain in their C-terminal end a highly conserved 650 
amino acid sequence which includes type 2 or EGF repeats and  type 3 repeats or calcium-binding 
domain conforming what has been termed the "identity domain" [175]. In the N-terminal end 
these proteins have an oligomerization domain, a procollagen (Willebrand type C domain) and a 
type 1 repeats domain or properdin like domain (TSR) which are specific of group 1 [175, 176].  
Thrombospondin-1 (TSP1) is a homotrimer of about 450 KDa expressed during the development 
of tissues and organs [175]. It was first described in 1971 by Baenziger et al. [177] under the 
name Thrombin-sensitive protein, since it was released by platelets when these were stimulated 
by thrombin [177, 178]. TSP1 regulates multiple cellular events involved in tissue repair 
including hemostasis, cell adhesion, migration, proliferation, extracellular matrix expression and 
organization, and regulation of growth factor activity [173, 175]. This is possible due to its multi-
domain structure which interacts with several cell receptors and matrix proteins. E.g.  TSP1 binds 
and activates transforming growth factor beta (TGF-β) through TSR repeats domain, this domain 
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also binds to CD36, VEGF or heparin sulfate. N-terminal end interacts with heparin and α3β1, 
α6β1, α4β1 modulating angiogenesis and C-ternimal end binds to CD47 regulating vascular 
homeostasis [174]. In addition to physiologic repair, TSP1 is also expressed at elevated levels in 
many tissues undergoing fibroproliferative remodeling. The blockade of specific actions of TSP1 
or loss of TSP1 expression can attenuate pathologic tissue remodeling [179-181]. TSP1 was the 
first anti-angiogenic factor described [182] and acts directly on endothelial cells through its 
interaction with the CD36 surface receptor  [183].Transgenic mice deficient for TSP1 are viable 
and display a mild and variable lordotic curvature of the spine that is apparent from birth, an 
increase in the number of circulating white blood cells, with monocytes and eosinophils having 
the largest percent increases, and a reduction of TGF-β activation [184].  
TSP1 is also considered for its role in vascular health and disease. In the systemic vasculature, 
TSP1 modulates vascular response and at pathologic levels promotes vascular dysfunction [185, 
186]. In cells and animal models, over-active TSP1 signaling inhibits vasodilation in part by 
limiting nitric oxide production and signaling [170, 171]. In addition, TSP1 is reported to be 
involved in arteriosclerosis-associated vascular remodeling [187]. In the lung, TSP1 has been 
reported to be important in the maintenance of homeostasis [166, 167] and to inhibit growth of 
lung cancer [188, 189]. Beyond these functions, a role for TSP1 in promoting pulmonary 
vasculopathy is now being especially relevant. Previous reports have found that tsp1-/- mice are 
protected from hypoxia-mediated PAH [169, 190]. In addition, TSP1 is upregulated in lungs from 
PAH patients compared to non-PAH controls [169-172]. However, the molecular mechanisms by 
which hypoxia regulates TSP1 in the lung and its implication in PAH events are still unknown. 
Hypoxia and cancer 
Hypoxia is a hallmark of almost all kind of solid tumors as brain, prostate, kidney, breast, cervical 
or colon, among others. As a consequence of the abnormal and aberrant process of neoplastic 
growth in tumorigenesis, the proliferating cancer cells have not a well stablished vascular network 
that support oxygen and nutrient supply. Under such conditions tumor cells activate cellular 
responses to improve cell survival; increase angiogenesis, improve glycolytic flux to enhance 
energy production, and regulate autophagy or apoptosis. Furthermore, clinical studies reveal that 
solid tumors have also been shown to harbor hypoxic areas, maintaining survival of cancer cells 
via the HIFα pathway, this being associated with bad outcome and prognosis [129, 130]. It is well 
established that HIFs play an important role in tumor progression. Previous studies have reported 
that HIF1α, HIF2α and HIF3α are overexpressed in human cancers and their expression levels 
correlate patient mortality [129, 130]. Studies with knockout mice for HIF1α or HIF2α revealed 
differences in their contribution to promote tumor growth [191, 192]. In this respect, HIF1α and 
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HIF2α demonstrated opposite effects in ccRCC, while HIF2α drives tumor progression, HIF1α, 
whose expression is frequently lost, inhibits growth and predicts for better patient prognosis [193-
195]. Thus, the relative importance of HIFα in tumor growth probably depends on the type of 
tumor. Investigating specific functions of HIF1α and HIF2α in ccRCC, there were identified 
different target genes differently activated either by HIF1α or HIF2α with opposing effects on 
tumor growth [196, 197].  
Clear cell Renal Cell Carcinoma  
Kidney cancer is among the top ten most common cancers in the world. The most frequent type 
of renal neoplasm is RCC, which accounts for 85% of all renal malignancies. It is estimated that 
320,000 new cases will be diagnosed in 2016, with an approximated number of deaths around 
140,000 worldwide [198]. RCC is the most common malignant tumor of adult kidney, being 
tumor resection the only effective treatment [199], due to its resistance to chemotherapy [200] 
and radiotherapy [201]. ccRCC is a subtype of RCC that comprises 75-88% of cases [202]. 
Somatic gene mutations in vhl is the main cause in most primary sporadic ccRCCs [203], see 
steps of the ccRCC development in Figure 5. Moreover, VHL loss in animal models has clearly 
implicated this gene as a gatekeeper gene in the pathogenesis of ccRCC [66, 204].  
 
Figure 5: Scheme of ccRCC tumor 
formation. Mutations in the second 
allele of vhl facilitate the appearance of 
cysts. Additional mutations promote the 
formation of tumors. 
 
 
 
ccRCC is characterized by the accumulation of glycogen, phospholipids and neutral lipids [205], 
a well-defined plasma, they are also highly vascularized tumors with high expression of 
proangiogenic factors due to the loss of VHL and the presence of hypoxic foci. Both situations 
produce an accumulation of HIF favoring the increase in hypoxic response genes. VEGF is one 
of the most relevant gene induced in ccRCC and its inhibition have been used as a therapeutic 
approach to repress angiogenesis [206]. However, VEGF inhibition has not been enough to stop 
tumor growth, suggesting that there must be additional mechanisms involved. In this regard, HIF-
independent VHL functions have been shown to contribute to tumor growth [66, 76, 207, 208]. 
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Therefore, it is conceivable that new additional pathways still unknown might also contribute to 
the growth of these tumors. Previous results have identified that Vascular Cell Adhesion Molecule 
(VCAM-1) is regulated by VHL in ccRCC cell lines and may help to explain why these tumors 
are highly invasive [209-211].  
Vascular Cell Adhesion Molecule-1 
VCAM-1 or cluster of differentiation 106 (CD106) is a cell adhesion protein that belongs to the 
immunoglobulin (Ig) superfamily of proteins [212] and was first described as a cytokine-
inducible endothelial adhesion molecule [213, 214]. Generally, VCAM-1 is expressed on the 
luminal and lateral side of endothelial cells under inflammatory conditions, mediating rolling and 
adhesion of various subsets of leukocytes as a prerequisite for their recruitment from blood into 
tissues. [215, 216]. The integrin α4β1 (very late activation antigen-4, VLA-4) was identified as 
the ligand for VCAM-1 mediating the adhesion of leukocytes to endothelium [217-219] (Figure 
6). 
Figure 6: Monocyte recruitment by activated 
endothelium. Under inflammatory conditions 
endothelial cells express and show ICAM-1 and 
VCAM-1 to the lumen and capture monocyte trough 
Mac1 and VLA4 respectively.  
 
 
 
VCAM-1 is localized in lipid-raft-like platforms with the tetraspanins CD9, CD81, and CD151, 
referred as tetraspanin-enriched microdomains, suggested to support VCAM-1 surface expression 
and function [220-222]. Two alternative VCAM-1 splicing variants in humans have been 
identified, consisting of seven (7d) or six (6d) Ig-like domains, with domains one and four 
revealed as binding sites for VLA-4 [223]. VCAM-1 can also be cleaved from the endothelial 
surface to a soluble (s)VCAM-1, which is increased in various diseases [224]. In addition to its 
extracellular interaction, VCAM-1 intracellular terminus is connected to the actin cytoskeleton 
via Ezrin and Moesin clustering in a docking structure that anchor and partially embrace 
leukocytes [221, 225]. 
Although VCAM-1 expression has been mostly assigned to activated endothelium, it is also 
expressed on follicular dendritic cells, macrophages in the spleen and thymus, and Kupffer cells 
in the liver under non-inflamed conditions [226]. Because of its wide distribution in human tissues 
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and organs, VCAM-1 participates in many pathophysiological situations like autoimmune 
diseases, cardiovascular disease, or infections [227]. Furthermore, it has been reported that tumor 
cells as melanoma, osteosarcoma or kidney and naturally blood borne tumors like leukemia and 
lymphoma cell lines are positive for VLA-4, and its interaction with VCAM-1 on endothelium is 
crucial for metastasis [228, 229]. Others tumors show a high level of expressed VCAM-1, 
however, it does not give any advantage concerning the endothelial adhesion, invasion or 
transendothelial migration of tumor cells. Instead, it allows a strong adhesion and interaction with 
VLA-4 of monocytes and tumor-associated macrophages generating prosurvival signals to the 
tumor cells [230, 231]. On the other hand, there are tumors that show a downregulation of VCAM-
1, these include melanoma and carcinoma, [232], suggesting a tumor protecting mechanism by 
attenuating the immune response for immune infiltration. [233]. 
VCAM-1 is also expressed in renal epithelium [234] and it has been considered as a predictor of 
cancer-free survival in ccRCC [209-211], however the mechanisms underlying VCAM-1 
regulation in these tumors and why this ccRCC with high levels of VCAM-1 have a better 
prognosis are yet unknown. VCAM-1 expression is stimulated under inflammatory conditions by 
a multitude of signals like cytokines as tumor necrosis factor alpha (TNFα), ROS, high 
concentrations of glucose, (toll like receptor) TLR agonists, or shear stress [222, 235]. It is well 
established that NF-κB is one of the main regulator of VCAM-1 in many different cell types [236] 
and that NF-κB is activated by TNF-α, a cytokine produced by activated leukocytes and many 
other cell types that is involved in systemic inflammation [237].  
Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells 
Hypoxia stimulates a complex cell signaling network in cancer cells, some of them regulated by 
HIF, as previously shown. In addition, there are other pathways that interact with each other 
causing positive and negative feedback loops and enhancing or diminishing hypoxic effects. NF-𝜅B is a family of transcription factors implicated in processes such as inflammation, apoptosis, 
proliferation, and development which are ubiquitously expressed in mammalian cells. NF-𝜅B 
subfamily is composed by five members; p65 (RelA), c-Rel, RelB, p105/p50 (NF-𝜅B-1) and 
p100/p52 (NF-𝜅B-2) that share a conserved N-terminal REL homology domain (RHD). This 
domain is responsible of dimerization, nuclear translocation and DNA binding. DNA binding 
occurs in special conserved sequences called 𝜅B elements or NF-𝜅B response elements (NRE). 
In addition, RelA, c-Rel and RelB contain C-TAD that are important for transcriptional activation 
[238, 239]. I𝜅B family (most known I𝜅B𝛼, I𝜅B𝛽, I𝜅B𝜀) have an ankyrin repeat domain (ARD) 
that binds to the RHD of NF-𝜅B family. I𝜅B proteins function as NF-𝜅B inhibitors sequestering 
NF-𝜅B in the cytosol. I𝜅B kinases (IKK) phosphorylate I𝜅B upon cell stimulation, which leads 
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to their ubiquitination and proteasomal degradation. Degradation and processing of the precursors 
p105 and p100 generate the proteins p50 and p52 respectively, which form dimeric complexes 
with RelA, c-Rel and RelB. These complexes go into the nucleus and activate genes under 𝜅B 
elements. [238, 239]. NF-𝜅B activation is controlled in a cell/tissue specific way by two major 
pathways depending on the stimulus and the members of the NF-𝜅B family that are being 
expressed. These two pathways are generally described as canonical and non-canonical NF-𝜅B 
pathways, although in some cases it is difficult to determine which is acting due to the crosstalk 
between them [240] (Figure 7). 
In the canonical pathway, signaling cascades are induced upon stimulation by pro-inflammatory 
cytokines (for instance; TNF𝛼, IL1), pathogen-associated molecular patterns (PAMPs) from 
bacteria and viruses, B- or T-cell antigen receptor (BCR or TCR) agonists, chemicals or radiation. 
Its activation culminates with the activation of the IKK complex formed by IKK𝛼 IKK𝛽 and 
IKK𝛾 (NEMO). When the IKK complex is activated, IKK𝛽 phosphorylates I𝜅B𝛼, leading to its 
K-48-linked ubiquitination and proteasomal degradation [241]. This enables the NF-𝜅B dimers 
(the most abundant being p65–p50) to accumulate, bind to NREs, and activate NF-𝜅B target genes 
[242, 243].  
In the noncanonical NF-κB pathway, NF-κB2 p100/RelB complexes are inactive in the 
cytoplasm. Signaling is restricted to a subset of TNF family members such as lymphotoxin (LT𝛽), 
B-cell activating factor (BAFF) and CD40L, although there are numerous cases in which 
canonical NF-𝜅B activator can induce RelB-p52 translocation into the nucleus and gene 
transcription [238, 239]. This signaling activates the kinase NF-κB-inducing kinase (NIK), which 
in turn activates IKKα complexes that phosphorylate C-terminal residues in NF-κB2 p100. 
Phosphorylation of NF-κB2 p100 leads to its ubiquitination and proteasomal processing to NF-
κB2 p52. This creates transcriptionally competent NF-κB p52/RelB complexes that translocate 
into the nucleus and induce target gene expression (Figure 7). As we have mentioned before, it is 
well established that NF- B is one of the main regulator of VCAM-1 in many different cell types 
[236]. NF- B is activated by the TNF-α [237], and despite it is thought that it can only induce 
NF- B through the canonical pathway, there are numerous reports showing that TNF-α can 
induce both, canonical and non-canonical NF- B pathways [244-247]. Previous studies 
demonstrate that VHL loss induces heightened activity of NF- B classical pathway [93, 94], in 
addition, NF-κB activation is a critical component in the transcriptional response to hypoxia [125]. 
However, the molecular mechanisms underlying VHL-mediated suppression of NF-κB have not 
been completely elucidated.  
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Figure 7: Molecular model of NF-κB activation pathways. Several stimuli trigger different pathways 
that induce IKKs. Activation of IKKs promote the phosphorylation of I𝜅B and its subsequent degradation 
by the proteasoma. This liberates P50 or P52 allowing dimerization with Rel proteins and transactivation. 
Note different pathways for canonical or non-canonical pathways.  
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OBJECTIVES 
In this thesis, hypoxia will be treated from two points of view, as the cause or as the consequence 
of a pathological process. Although there are many pathological conditions in which hypoxia is 
involved, we will focus on the role of hypoxia in pulmonary arterial hypertension PAH as the 
cause of the disease, and in clear-cell renal carcinoma (ccRCC) as a consequence. Taking into 
account all the previously mentioned in the introduction of this thesis these are the objectives 
proposed in each section: 
1. Hypoxia, TSP1 and PAH. 
Based on the role of TSP1 in vascular homeostasis and its recent implication in hypoxic PAH, we 
postulate that TSP1 could be activated through a hypoxia-mediated mechanism and its regulation 
may have a special relevance during PAH events. Therefore, we propose the following aims in 
this matter: 
1.1 Analyze the cellular source involved in the induction of TSP1 in the lung under hypoxia  
1.2 Elucidate the mechanisms by which hypoxia induces TSP1 levels in the lung 
1.3 Study the contribution of TSP1 to functional aspects and cellular events during PAH.  
1.3.1 Effects of TSP1 on vascular remodeling 
1.3.2 Effects of TSP1 on endothelial dysfunction and cell contractility  
2. Hypoxia, ccRCC and VCAM-1 
Taking into account all the previous background, we hypothesized that decreased levels of 
VCAM-1 in ccRCC, which has been clearly related with a worst prognosis, might be due to the 
effects of VHL loss or hypoxia. In addition, given that NF-κB activation is a critical component 
in the transcriptional response to hypoxia, and on the other hand it is a transcriptional regulator 
of VCAM-1, it is plausible that the regulation of this pathway by VHL or hypoxia modulates the 
levels of VCAM-1 in these tumors. In order to challenge our hypothesis our aims were:  
2.1. Elucidate the mechanism by which hypoxia and VHL loss regulate VCAM-1. 
 
2.2. Study the contribution and functional effects of VCAM-1 in these tumors. 
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MATERIALS AND METHODS 
 
Animals.  
Age matched male C57BL/6 WT and tsp1-/- mice (stock numbers 000664, 006141 respectively) 
were obtained from the Jackson Laboratory (Bar Harbor, ME). Vhlfl/fl-UBC-Cre-ERT2, 
HIF2αfl/fl-UBC-Cre-ERT2 and HIF1αfl/fl-UBC-Cre-ERT2 mice were used to generate VHL 
(vhl-/-), or HIF2α (hif2α-/-) knockout mice respectively or double VHL/HIF2α, VHL/HIF1α 
knockout mice (vhl-/-/hif2α-/-, vhl-/-/hif1α-/- respectively). The gene deletion procedure employed 
to generate these animals was previously described [248, 249]. To induce hypoxia in vivo, mice 
were placed in an airtight chamber with inflow and outflow valves, and infused with a mixture of 
10% O2 and 90% N2 (Carburos Metálicos). When mice were exposed to hypoxia in combination 
with Semaxanib (SU5416), a potent and selective VEGFR(Flk-1/KDR) inhibitor, animals were 
injected subcutaneously with SU5416 (20 mg/kg) or vehicle (DMSO) once a week. All mice in 
this work were sacrificed by first administering inhalation general anaesthesia (isoflurane 1.5%) 
followed by cervical dislocation. All studies were performed under the supervision of the Head 
of Animal Welfare and Health with a protocol approved by the Committee for Research and 
Ethics of the Universidad Autonoma of Madrid in accordance with Spanish and European 
guidelines (Directive 2010/63/EU of the European Parliament). 
Reagents. 
 
Table 1: Most important reagents employed in this work. 
 
Reagents 
Reagent Manufacturer #Catalog Use /Description [C] 
TSP1 Athens 
16-20-
201319 
TSP1 extracted from human 
platelets. 
20 mg/mL 
TNF-α RyD 210-TA-005 
RD 
Recombinant human TNF-α from 
E.coli used to activate NFkB 
20 ng/mL 
IFN-𝛾 RyD 285-IF-100 Recombinant human IFN-𝛾 from E.coli used to activate human 
monocytes. 
100 U/ml 
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SM7368 Sigma Aldrich 380623-76-7 TNF-α inhibitor. 20 µM 
LSKL AnaSpec AS-60877 TSP1 inhibitor. 1 µM 
SB 431542 RyD 1614/1 TGFβ inhibitor. 10 µM 
DMOG Sigma Aldrich 89464-63-1 Prolyl hydroxylases Inhibitor 1 mM 
DAPI Sigma Aldrich 28718-90-3 
Cell permeable fluorescent minor 
groove-binding probe for DNA. 
1/1000 
Alexa Fluor® 
Phalloidin 568 
Thermo Fisher 
Scientific. 
A12380 
Phalloidin is a toxin which binds 
and stabilizes F-Actin. Label F-
Acting in Alexa Fluor 568. 
1/200 
Alexa Fluor® 
Phalloidin 647 
Thermo Fisher 
Scientific 
A22287 
Phalloidin is a toxin which binds 
and stabilizes F-Actin. Label F-
Acting in Alexa Fluor 647. 
1/100 
DPO1 (diphenyl 
phosphine 
oxide-1) 
Sigma Aldrich 43077-30-1 Inhibits Kv1.5 channels. 1-2 µM 
XE-991 Sigma Aldrich 122955-42-4 Inhibits Kv7 channels. 0.3 µM 
Ionomycin Sigma Aldrich 407952 Calcium Salt. 1 µM 
LPS Sigma Aldrich 297-473-0 
Stimulates cells of the innate 
immune system by (TLR4) 
2 µg/mL 
cd14-Beads Miltenyi 130-050-201 Beads coated with cd14 to isolate 
human monocytes. 
20 µL/107 
total cells 
FITC-dextran 
(70 kDa) 
Sigma Aldrich 
FD70S-
100MG 
Dextran labeled with FITC used 
in perfusion studies in cell 
monolayers 
10 mg/mL 
Calcein-AM Sigma Aldrich 148504-34-1 
It is a fluorescent dye with 
excitation and emission 
wavelengths of 495/515 nm, 
respectively. 
2.5 mM 
Fluo4-AM 
Thermo Fisher 
Scientific 
F14201 
Fluorescent Calcium Probe with 
excitation and emission 
wavelengths of 494/506 nm, 
respectively. 
1 µM 
SU 5416 
Semaxanib 
Sigma Aldrich S8442 
SU 5416 is a VEGFR inhibitor 
used to exacerbate PAH 
remodeling in animal models. 
20 mg/kg 
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Antibodies. 
 
Table 2: All the antibodies employed. 
 
Primary Antibodies 
Antibody Host Used for Manufacturer #Catalog Technique [C] 
TSP1 Ab11 
(Cocktail) Mouse 
Human, 
Mouse 
Neomarkers MS-1066-P1 WB 1/500 
TSP1 Ab6.1 Mouse Human, 
Mouse 
Thermo Fisher 
Scientific 
MA5-13398 IF 1/100 
anti-α-
Tubulin Mouse 
Human, 
Mouse 
Sigma Aldrich T6199 WB 1/2000 
anti-β-
Actin 
Mouse 
Human, 
Mouse 
Sigma Aldrich A5441 WB 1/2000 
anti-
Vinculin 
hVIN-1 
Mouse Mouse Sigma Aldrich V9131 IF 1/400 
rabbit anti-
ZO-1 
Rabbit Mouse 
Thermo Fisher 
Scientific 
40-2300 IF 1/200 
anti-HIF1α Mouse Human RyD mab1536 WB 1/500 
anti-HIF1α 
C-term 
Rabbit Human 
Cayman 
Chemical 
Company 
10006421 WB 1/500 
anti-HIF2α 
Ab199 Rabbit 
Human 
Mouse 
Abcam ab73895 WB 1/500 
anti-
VCAM-1 
H-276 
Mouse Human 
SantaCruz 
Biotechnology 
sc-8304 WB 1/1000 
anti-VHL 
(VHL40) Mouse Human 
SantaCruz 
Biotechnology 
sc-135657 WB 1/500 
anti-NIK Rabbit Human SantaCruz 
Biotechnology 
sc-7211 WB 1/500 
anti-NF-κB 
p65 (C-20) 
Rabbit Human 
SantaCruz 
Biotechnology 
sc-372 WB 1/500 
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anti-NF-κB 
p52 (k-279 Rabbit Human 
SantaCruz 
Biotechnology 
sc-298 WB 1/500 
anti-NF-κB 
p50 (E-10 
Mouse Human 
SantaCruz 
Biotechnology 
sc-8414 WB 1/500 
anti-NF-κB 
Rel B (D-4) 
Mouse Human 
SantaCruz 
Biotechnology 
sc-48366 WB 1/500 
anti-IKKα 
(3G12) Mouse Human 
Cell Signaling 
Technology 
682 WB 1/500 
anti-SMA 
(clone 1A4), Mouse 
Human 
Mouse 
(Dako, 
Carpinteria, 
CA) 
M0851 IF 1/400 
anti-SMA-
cy3 
Mouse 
Human 
Mouse 
Sigma Aldrich C6198 IF 1/400 
(CNN1) 
EP798Y 
Rabbit 
Human 
Mouse 
Abcam ab46794 IF 1/400 
Secondary Antibodies 
Antibody Host 
species 
Specificity Manufacturer Catalog 
Number 
Use [C] 
GAM-488 Goat Mouse IgG 
Thermo Fisher 
Scientific 
A11029 IF 1/200 
GAM-568 Goat Mouse IgG 
Thermo Fisher 
Scientific 
A-11031 IF 1/200 
GAR-488 Goat Rabbit IgG Thermo Fisher 
Scientific 
A-11034 IF 1/200 
GAR-568 Goat Rabbit IgG Thermo Fisher 
Scientific 
A-11036 IF 1/200 
RAM-HRP Rabbit Mouse IgG 
Dako 
Diagnosticos 
SA 
P0260 WB 1/1000 
DAR-HRP Donkey Rabbit IgG GE Healthcare NA934V WB 1/2000 
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Cell culture.  
Primary Cells 
Primary murine pulmonary artery vascular smooth muscle cells (mPASMCs) were obtained from 
8-10 weeks-old male C57BL/6 WT and tsp1-/- mice. Mice were sacrificed as previously described 
and flushed with sterile PBS to remove blood, and lungs were then extracted under sterile 
conditions. Pulmonary arteries were carefully dissected and the adventitia was removed under a 
dissecting microscope. Arteries were then cut into rings (1.8–2  mm length) and explanted in a 
35 mm culture dish in Dulbecco's Modified Eagle's Medium (DMEM) with 20% FBS, penicillin 
(100 units/mL), streptomycin (100 units/mL), amphotericin B (100 µg/mL), HEPES (200 µg/mL) 
and Heparin 500x (1 ml/500 mL media). After 3 days, cells were maintained in media with 10% 
FBS at 37ºC and 10% CO2. The cells migrated from the explants within 6-9 days and grew to 
confluence in approximately 2 weeks. Cell purity was confirmed by immunostaining with mouse 
anti-SMA and rabbit anti-Calponin-1 (CNN1) antibodies.  
Primary pulmonary-derived fibroblasts (mFIB) were isolated by enzymatic digestion with 
collagenase A from chlostridium histolyticum (Sigma-Aldrich). Briefly, mice were sacrificed as 
above and lungs were perfused with PBS, extracted, cut into small pieces and then incubated with 
3 mL of 2 mg/mL collagenase solution for 30 min. After digestion cells were washed twice in 
DMEN with 10% FBS and then cultured in DMEM supplemented with 20% FBS, penicillin (100 
units/mL), streptomycin (100 units/mL) and 1% HEPES buffer. Cells were grown for two days 
and then cultured for an additional three days in minimum media with 5% FBS to minimize 
contaminating endothelial or smooth muscle cells. Following, these cells were maintained in 
media with 10% FBS at 37ºC and 5% CO2.  
Human pulmonary arterial endothelial cells (hPAEC), smooth muscle cells (hPASMC) and 
human umbilical vein endothelial cells (HUVEC) were obtained from ATCC (PCS-100-022, 
PCS-100-023 or CRL-1730 respectively) and were cultured following manufacturer´s 
recommended specifications. Human pulmonary arterial fibroblast (hPAFIB) were obtained from 
ScienceCell (#3120) and were cultured following manufacturer´s recommended specifications.  
Myeloid cell isolation and culture. Peripheral blood mononuclear cells were purified by Ficoll 
gradient centrifugation from pooled human buffy coats obtained from the Hospital Universitario 
de la Princesa (Madrid, Spain). Myeloid cells were isolated from mononuclear cell populations 
by positive selection for CD14 by magnetic beads immune selection according to the 
manufacturer's directions (Miltenyi Biotech, Auburn, CA). All studies with human cells were 
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conducted with the approval of the Human Subjects Institutional Review Board of the Hospital 
Universitario de la Princesa.  
Cellular Lines 
Renal carcinoma cell lines 786-O (CRL-1932),  Caki-1 (HTB-46), Caki-2 (HTB-47) and ACHN 
(CRL-1611) were from the American Type Culture Collection (ATCC: Rockville, MD, USA), 
and the RCC4 cell line was kindly provided by Dr. W. Kaelin (Dana-Farber Cancer Institute, 
Boston, MA). Cells were cultured in DMEM (Dulbeco's modified Eagle's medium) containing 
10% (v/v) FBS (fetal bovine serum), 100 units/ml penicillin/100µg/ml streptomycin (antibiotics). 
Chinesse Hamster Ovary cells, CHO.K1 (ATCC, #CCl-61) were cultured in 1% glucose DMEN, 
10% FBS and antibiotics. 786-O and RCC4 cells were stably transfected with the vectors 
pRc/CMV or HA-VHL-pRc/CMV, in the text named as pRv or VHL (30 kDa) respectively, 
provided by Dr. W. Kaelin through Addgene (plasmids # 20814 and 19999 respectively). 
Transfected cells were selected with 1 mg/ml G418 sulfate. Additionally, we used 786-O 
expressing the naturally occurring type 2C VHL mutant L188V or a non neddylateable version 
of VHL termed RRR (in which lysines (K) 159, 171, and 196, have been substituted by an arginine 
(R), with K159 being an essential residue for neddylation. As a control for this mutant we used 
786-O cells transfected with another version of VHL (KRR) that carries mutations only at Lys171 
and Lys196 (which do not interfere with the normal VHL function) [250]. These mutants were 
kindly provided by Dr. Michael Ohh (University of Toronto, Canada). Cells were maintained in 
culture at 37ºC in the presence of 5% CO2 and 21% O2 (normoxia) and grown in DMEM 
containing 10% (v/v) FBS and antibiotics.  For hypoxic experiments, cells were incubated at 37ºC 
in an Invivo2 400 hypoxia workstation (Ruskinn Technology, West Yorkshire) in the presence of 
5% CO2 and 0.5-1 % oxygen for the times indicated.  
HIF reporter in vitro assay.  
Tsp1 Hypoxia Response Elements (HRE1: GGCGGCTGACGTCCCATCCCGAAGA and 
HRE2: CCAAGGCTGCGTGGGCGGGCACCGA) were introduced in the luciferase reporter 
plasmid pGL4.23 vector (Promega) between Kpn1 and Hind3, generating pGL4.23-HRE1 and 
pGL4.23-HRE2 with three copies in tandem. As an HRE validated control the HIF-responsive 
firefly luciferase reporter, expressing the luciferase gene under the control of nine tandem copies 
of the VEGF hypoxia response element (9xHRE) [251] was used. Renilla, pRL-SV40 Vector 
(Promega) was used as an internal control. In addition, to test HIF functional activity, we used 
retroviral vectors pRV-GFP encoding HIF mutated constitutive active forms, HIF2α (P-A)2 or 
HIF1α (P-A)2 or a mutation lacking transcriptional activity HIF1α(P-A)2bHLH [193]. CHO.K1 
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were cultured in p24 plate at the 75% optimum confluence, and then cells were transiently 
transfected with the pRV vectors (0,25 µg), luciferase vectors (0,25 µg) and Renilla (0,05 µg) 
using 2,5 µg of the transfection reagent jetPEI (Polyplus) per well. After 24 h reporter activity 
was determined using the Dual-Luciferase Reporter Assay System (Promega) according to the 
manufacturer's instructions. Firefy luciferase activity was normalized based on the Renilla 
luciferase activity and Luciferase activity was measured using a Glomax Multidetection 
(Promega). 
Human tissues  
Control non-PAH and end-stage PAH lungs were obtained immediately following explantation 
under ongoing University of Pittsburgh IRB protocols (970946 and PRO14010265). Informed 
consent was given for the use of human samples and the study conformed to the principles 
outlined in the Declaration of Helsinki. Under sterile conditions and employing magnification, 
distal 5th order PAs were dissected for further processing using a minimal “touch” technique to 
prevent tissue injury.  
Tumor samples were collected from non-selected patients who underwent nephrectomy at 
Yokohama City University Hospital and its affiliated hospitals. All specimens were snap-frozen 
with liquid nitrogen and stored at −80 ◦C until nucleic acid extraction. All tumors were confirmed 
to have occurred sporadically according to the patients’medical records. The histopathology of 
the tumors was classified according to the classifications recommended by the Union 
Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer [252]. 
Tumor stage and grade were determined after surgical treatment according to the tumor–node–
metastasis (TNM) classification [252]. Written informed patient consent was obtained for 
studying gene expression profiles and the study protocol was approved by the institutional ethics 
committee.   
Immunofluorescence.  
Cells were seeded onto fibronectin coated 13-mm glass coverslips (5 µg/mL fibronectin) and then 
incubated in normoxia or hypoxia (1% O2) for 24 h. Afterwards cells were fixed with 4% 
paraformaldehyde in PBS and permeabilized with 0.5% Triton in PBS with 1% BSA, 100 µg/mL 
gammaglobulin and 0.05% azide. Cells were blocked for 30 min with 5% BSA in PBS with 100 
µg/mL gammaglobulin and 0.05% azide and stained with the indicated primary antibodies 
followed by Alexa Fluor 488 or 568 labeled secondary antibodies and Phalloidin-conjugated 
Alexa 568 or 647. DAPI to stain cell nuclei was used. Cells were mounted in Prolong Gold 
(Invitrogen) and imaged with a Leica fluorescence microscope (Leica DMR 020-525.024 
MATERIALS AND METHODS 
 
 
50 
fluorescence microscope). Images were taken with camera Leica Microsystems CMS GmbH, D-
35578 Wetzlar, DFC360 Fx (115470000) and the following objetives: Leica HCX PL APO 
40x/1.25-0.75 OIL, Leica HCX PL APO 63x1.32-o,6 oil or dry objective Leica N PLAN 
10X/0.25. Imaging software used was Leica Application Suit (LAS v4.1). Focal adhesion (FA) 
contacts were quantified with ImageJ following the protocol described by Horzum U. et al. [253].  
Protein expression by Western blot analysis.  
Lysates of snap frozen lung tissues (murine and human), isolated primary cells (human and 
murine) and human RCC cell lines were prepared in RIPA buffer (50 mM TRIS (pH 7.5), 1% 
NP-40, 1 mM EDTA, 125 mM NaCl, 0.25% sodium deoxycholate, 1mM sodium orthovanadate, 
1 mM sodium fluoride and 1X phosphatase/protease inhibitors cocktail (Roche Applied Science, 
Hercules, CA). Lysates were centrifuged at 17,000xg for 20 min. A bicinchoninic acid assay 
(BioRad, Life Sciences Research, Hercules, CA) was used to quantify total protein. Lysates (30 
µg/lane) mixed with 1X reducing Laemmli buffer (Bio-rad) were boiled at 95°C for 5 min, 
electrophoretically separated onto SDS-page gels and transferred onto nitrocellulose membranes 
(BioRad). Blots were probed with primary antibody to the respective proteins and afterwards with 
HRP-conjugated secondary antibodies. Proteins were visualized with HRP substrate (Luminata 
Forte, Millipore) on ImageQuant LAS 4000 (GE Healthcare Life Sciences). Alternatively, human 
samples were blocked in Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE), incubated 
overnight at 4°C with primary fluorescent labeled antibodies and visualized on an Odyssey 
Imaging System (Licor). The intensity of the bands was quantified using ImageQuant 5.2 or 
ImageJ (NIH, Bethesda, MD). 
Real Time quantitative PCR analysis.   
Analysis of mRNA to determine gene expression levels or analysis of heterogeneous nuclear 
RNA to determine transcriptional state of genes was performed by quantitative reverse 
transcription polymerase chain reaction (RT-Q-PCR). Cells were grown to 95% confluence in 60 
mm culture dishes, and the total RNA was isolated from cells using the Trizol RNA Isolation 
System (Invitrogen). RNA (1 µg/sample) was reverse-transcribed to cDNA with Improm II RT 
(Promega, Madison, WI) in a final volume of 20 µl. For RT-Q-PCR 1 µl of cDNA was amplified 
with the specific primers pairs and polymerase chain reaction amplifications were performed 
using Power SYBR green PCR Master Mix (Applied Biosystems). The data were analyzed using 
StepOne Plus Software (Applied Biosystems, Carlsbad, CA). The primer pairs used to analyze 
tsp1 were designed to amplify exon 2 and 3 of the tsp1 sequence, which is missing in tsp1-/- mice. 
Primers used for the analysis of heterogeneous nuclear RNA (hnRNA) of VCAM-1, mRNA 
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before splicing modification were designed for exon 3 and intron 3-4. All values were controlled 
with β-Actin gene expression levels.  
Table 3: Primer pairs of genes analyzed by RT-Q-PCR  
 
Oligos Species 5´- 3´ Forward Sequence 5´- 3´ Reverse Sequence 
β-Actin Human 
Mouse 
CGATGCCTGAGGCTCTTT TGGATGCCACAGGATTCCA 
tsp1 Mouse GGTGTCCTGTTCCTGTTGCA CCGTTATCTCCCCCAGACTCT 
tsp1 Human ACTGGGTTGTACGCCATCAGG CTACAGCGAGTCCAGGATCAC 
Kv1.5 Mouse CTGGGTCAGCAAGAGCCATT TCAGGCAGAGTCTCCAAGCA 
Hif1α Human 
AGCCGAGGAAGAACTATGA 
ACATAA GTGGCCTGTGCAGTGCAA 
Hif2α Human CTCATCCCTGCGACCATGA TTCCCAAAACCAGAGCCATT 
Vhl Human CGCCGCATCCACAGCTA TGTGTCCCTGCATCTCTGAAGA 
vcam-1 Human GTTCCTAGCGTGTACCC GCTGACCAAGACGGTTG 
vcam-1 
Human 
(hnRNA) 
CCACAGTAAGGCAGGCTGTAAA GCAGCTTTGTGGATGGATTCA 
vcam-1 
Human 
Clinical 
Samples 
CAAAGGCAGAGTACGCAAACAC CTGGCTCAAGCATGTCATATTCAC 
glut-1 Human TCAACCGCAACGAGGAGAA CTGTCCCGCGCAGCTT 
phd1 Human GCGCTGCATCACCTGTATCTAT CCGCCATGCACCTTAACG 
phd2 Human CCCTCATGAAGTACAACCAGCAT CATCTGCATCAAAATACCAAACAGT 
phd3 Human 
Mouse 
TGCATCACCTGCATCTACTATCTG TACATGGTGGGATCCTGCG 
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For the analysis of VCAM-1 in human clinical samples the probe (5-6FAM-
CAGAGATACAACCGTCTTGGTCAGCCCTTTAMRA-3) was used. PCR amplification was 
done using the iCycler iQ Real-time quantitative PCR Detection System (Bio-Rad Laboratories, 
Hercules, CA). The amount of product was measured by interpolation from a standard curve. In 
each experiment, at least two independent RT-Q-PCRs were done to obtain the mean expression 
signal values. Values were controlled with β-Actin gene expression levels.     
siRNA-mediated gene silencing.  
siRNA experiments were carried out with specific pools of siRNAs directed against human tsp1 
(sc-36665), vcam-1 (sc-29519), vhl (sc-36816), hif1α (sc-35561), hif2α  (sc-35316), phd1 (sc-
45616), phd2 (sc-45537), phd3 (sc-45799), nik (sc-36065), ikkα (sc-29365), p52 (sc-29409) and 
p50 (sc-29407) or with a non-targeted pool of control Scr siRNAs (sc-37007) from Santa Cruz 
Biotechnology (Santa Cruz, Heidelberg, GE). Cells were transfected with Lipofectamine 2000 
(11668019, Invitrogen), according to the manufacturer's instruction. Two days after transfection 
silencing efficiency was analyzed and cells were used for experiments. 
Cell migration.   
Cells were serum starved for 3 h and then allowed to migrate across Transwell filters (6.5-mm 
diameter, 8 µm pore size, Costar Corning, NY) for 7 h at 37ºC and 5% CO2 under normoxia or 
hypoxia (1% O2). As a chemoatractant DMEM with 20% FBS was added into the lower chamber 
while basal media was used as a negative control. Non-migrating cells on the upper surface of the 
membrane were gently removed with Q-tips, while the migrating cells on the lower surface were 
fixed, stained with Diff-Quick (International Reagent, Kobe, Japan) and counted under the 
microscope (Leica DMR 020-525.024 fluorescence microscope) with a dry objective Leica N 
PLAN 10X/0.25. 
Transwell permeability assays.  
Transendothelial flux of FITC-dextran (molecular mass of 70 kDa; Sigma) was used as an index 
of endothelial paracellular permeability. hPAEC were seeded at passage five-eight at a density of 
2-3 × 104 cells/cm2 on Transwell polycarbonate filters, 6.5-mm diameter, 0.4 µm pore size (Costar 
Corning, NY). FITC-dextran (10 mg/mL) in cell medium was added to the upper chambers of the 
Transwell system and the monolayers were then exposed for 6-7 h to normoxia or hypoxia (1% 
O2). Transfer of FITC-dextran across hPAEC monolayers was quantified after 1h in 100-µL taken 
from the lower chamber. As a permeability control, we treated hPAEC monolayers with 1mM 
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EGTA, which alters intercellular junctions increasing the FITC-dextran flux across the cell 
monolayer. The fluorescence was measured with a spectrophotometer (FLUOstar Omega, BMG 
Labtech) using 480 and 515 nm as the excitation and emission wavelengths, respectively. The 
absolute quantities of FITC-dextran in experimental samples were determined using a 
standardization curve. 
Vascular contractility.  
Murine pulmonary arteries were carefully dissected free of surrounding tissue, cut into rings (1.8-
2 mm length) and maintained for 16 hours under normoxic or hypoxic (1% O2) conditions in 
basal medium (DMEN with penicillin (100 units/mL) and streptomycin (100 units/mL)). 
Afterwards vessel segments were mounted on a wire myograph in the presence of Krebs 
physiological solution. To maintain normoxic or hypoxic conditions, buffer solutions were 
continuously aerated with 21% O2, 5% CO2 and 74% N2 (pO2=17–19kPa) or with 95% N2 and 
5% CO2 (pO2=2.6–3.3kPa) respectively, and stretched to a transmural pressure equivalent to 30 
mHg. Contractility was recorded by an isometric force transducer and a displacement device 
coupled to a digitalization and data acquisition system (PowerLab). To confirm smooth muscle 
viability arteries were first stimulated by raising the K+ concentration of the buffer to 80 mmol/L 
and then allowed to recover. Arteries were then stimulated with serotonin (5-HT, 10 µM) and 
treated with a concentration-response curve of the endothelium-dependent and independent 
vasodilators acetylcholine (Ach, 0.001-10 µmol/L) or sodium nitroprusside (SNP, 0.01-1000 
nmol/L). In other experiments vessels were pre-treated with XE991 (0.3 µmol/L) or diphenyl 
phosphine oxide-1, DPO1 (1 µmol/L), to inhibit Kv7 and Kv1.5 channels respectively.  
Life cell calcium measurement:  
Calcium was measured in mPASMC 10 days after cell harvesting from age matched male WT 
and tsp1-/- mice. Cells were seeded on Lab-Tek 4 wells (Chambered Coverglass, Thermo 
Scientific). When cells reached 70% confluence they were incubated for 16 h in normoxic or 
hypoxic (1% O2) conditions. They were then washed with 4,5 g/L glucose supplemented Hank's 
Balanced Salt Solution (HBSS) and incubated at 37ºC, 5% CO2 for 30 min with the cytosolic 
calcium probe Fluo-4 AM at 1 µmol/L in HBSS glucose. After incubation, the wells were washed 
and incubated for additional 30 min. Next, cells were time lapse photographed with a Leica SP5 
Confocal Microscope every 7 seconds using a Leica dry objective HC PL APO 20X/0,75 CS2 
and illuminated with a 488nm-Ar laser using spectral filtering and hybrid (HyD) detectors. To 
interrogate the role of potassium Kv1.5 channels in this process cells were treated with DPO1 (2 
µmol/L). Images were collected using Leica TCS software, and the increase in the fluorescence 
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peak was quantified using ImageJ (NIH, Bethesda, MD). As a control of calcium measurement, 
we quantified the fluorescence of cells treated with Ionomycin (1 µmol/L). 
Flow cytometry analysis.  
VCAM-1 levels on the cell surface were measured by flow cytometry. 786-O cells and their 
counterparts stably expressing VHL were cultured under normoxia or hypoxia (0.5% O2) for 24 
h. Afterwards cells were washed and resuspended in PBS at 1x106 cells/ml, then incubated with 
anti-VCAM-1 antibody for 1h at 4ºC. After this time non-bound antibody was washed out and 
the cells were incubated with Alexa Fluor 488 goat anti-mouse secondary antibody for 30 min at 
4ºC. VCAM-1 expression was quantified using a FACS®Calibur flow cytometer (Becton 
Dickinson). 
Co-culture adhesion experiments.  
786-O cells stably transfected with VHL or empty vector (pRv) and with siScr or siVCAM-1 
were grown at confluence in a 24-multiwell plate (30x103 cells/well). When indicated, cells were 
grown under hypoxia (0.5% O2) for 24 h previous to adhesion experiments. THP-1 or U937 
monocytic cell lines from the American Type Culture Collection (ATCC, Rockville, MD, USA) 
were labelled with the fluorescent dye calcein AM 2.5 mM in serum-free medium for 20 min at 
37ºC. Then cells were washed and resuspended in adhesion buffer (HEPES-buffered Hanks’ 
balanced salt solution containing 1% bovine serum albumin, 2 mM MgCl2, 2 mM CaCl2, and 0.2 
mM MnCl2) and added (60x103 cells/well) on top of the ccRCC monolayer and both cell lines 
were allowed to interact for 20 min at 37ºC. When indicated, cells were incubated with anti-α4 
(HP2/1) [254], anti-β1 (VJ1/14) [255] or anti-αL (TS1/11) [256] blocking antibodies, kindly 
provided by Dr Sanchez-Madrid (Universidad Autónoma of Madrid, Madrid, Spain). After 15 
min at 37ºC membranes were washed with adhesion buffer. Afterwards unbound THP-1 or U937 
monocytic cells were gently removed and bound monocytes were fixed with 3% 
paraformaldehyde and counted under a fluorescence microscope (Leica DMR 020-525.024 
fluorescence microscope). Images were taken with camera Leica Microsystems CMS GmbH, D-
35578 Wetzlar, DFC360 Fx (115470000), objective Leica HCX PL APO 100x/1.40-0.7 OIL CS 
and the imaging software used was Leica Application Suit (LAS v4.1). 
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Cytotoxicity assays.  
These assays were performed with the xCELLigence System (Roche) that measures electrical 
impedance across micro-electrodes integrated in the bottom of tissue culture plates. This provides 
quantitative information about the status of the adherent cells, including viability. Co-cultures of 
ccRCC (2500 cells) with M1 differentiated monocytic cells (activated with 100 U/ml INF-γ and 
2 µg/mL LPS, in a proportion of 1/60 respectively were monitored for 96 h with measures every 
5 min. Cellular index normalized with RTCA Software (Roche, Applied Science, Germany), was 
expressed as percentage of living cells.  
Passive CLARITY.  
Detailed protocol (modified from Dr Rinaman´s lab. [257]) used to clarify mice lungs,  
Table 4: Reagents for CLARITY. 
 
Reagent: Source/Product # 
40 % Acrylamide solution BioRad, 161-0140 
10X Phosphate-buffered saline, pH 7.4 Invitrogen, GIBCO 10010 
2,2-Azobis[2-(2-imidazolin-2-yl)propane] 
dihydrochloride (VA-044 initiator) 
Wako, 27776-21-2 
Paraformaldehyde aqueous solution, 16 % Electron Microscopy Sciences, 15710-S 
Boric acid  Sigma–Aldrich, B3637  
Sodium dodecyl sulphate (SDS) Promega, H5114  
2,20-Thiodiethanol Sigma–Aldrich, 166782 
Mineral oil Fisher Scientific # S25439A 
Solutions: 
1. Hydrogel solution: Paraformaldehyde (PF)- acrylamide. (Post-fixation solution) 1X (PBS, pH 
7.4; prepared by diluting 10X PBS 1:10 in dH2O) containing 4.0 % PF (vol/vol), 4.0 % 
acrylamide (vol/vol), and 0.25 % VA-044 initiator (wt/vol). Briefly, PF, acrylamide and VA-
044 were stirred into 1X PBS at room temperature to dissolve, then immediately chilled on ice 
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and kept cold until used within 1–2 h. Additional solution (30 ml/lung) was reserved for post-
fixation and hydrogel polymerization.  
2. Tissue clearing solution: 0.2 M boric acid (pH 8.5) containing 4.0 % sodium dodecyl sulphate 
(SDS).  
3. Rinsing buffer for immunofluorescent labeling (IFL):  0.5M boric acid (pH 8.5) containing 
0.1 % triton- X100.   
4. Antibody diluent for IFL:  0.5 M boric acid containing 0.1 % triton-X100 and 1.0 % normal 
donkey serum.  
5. Refractive index matching (RIM) medium: 2,20-Thiodiethanol (TDE) diluted to 
concentrations of 20, 40 and 60 % in 1X PBS. (RIM has to be conducted at RT without 
shaking). 
Protocol: 
Animals were sacrificed by first administering inhalation general anaesthesia (pentobarbital 
sodium, 130mg/kg) followed by cervical dislocation.  Mice were perfused transcardially with 10-
30 ml of ice-cold 1XPBS, and then transcardially and intratracheally with 50-100 ml of ice-cold 
hydrogel solution. Lungs were extracted and placed into 50 ml Falcon conical tubes containing 
30 ml of post-fixation hydrogel solution and stored overnight at 4ºC. To minimize exposure of 
hydrogel-immersed lungs to oxygen, a 1 cm-thick layer of mineral oil was gently laid over the 
top of the hydrogel solution before the tubes were tightly capped. The day after, hydrogel was 
polymerized at 37ºC for 3h in a water bath without shaking. Then, the excess of hydrogel of the 
organs was removed in order to make an easier clarification. At this point the organs can be cut 
into pieces for faster clarification, although tissues in this work were integrally clarified. 
Tissue samples were submerged into 40 ml of tissue clearing solution in 50 ml Falcon conical 
tubes and placed onto a rotating platform at 37ºC to enable passive clearing.  Clearing solution 
was replaced every day during the first week and subsequently three times a week until the tissue 
was visibly cleared. Tissues can be stored in clearing solution for up to 9 months at RT. Then, 
cleared samples were transferred into a 20 ml glass scintillation vial to perform IFL. First, samples 
were rinsed to remove residual SDS, then they were incubated for 72 h with the indicated primary 
antibodies (antibodies were diluted in IFL antibody diluent) and then rinsed with four changes of 
rinsing buffer along 24 h. Afterwards they were incubated for 72 h with the appropriated 
secondary antibody. Samples were finally rinsed and washed with 1XPBS for 24 h. Antibody 
incubations and rinses were conducted onto a rotating platform in a 37 °C incubator.   
Cleared tissue needs to be submerged in TDE solutions at progressively higher concentrations to 
achieve the correct refractive index matching (RIM). To that end, clarified organs were 
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sequentially submerged in 20%, 40% and 60% TDE solution for 4-12h each (time depends on 
tissue size). The tissues were washed (3xtimes) with fresh 60% TDE solution at RT for late 
imaging of IFL. (The 60 % concentration of TDE has a refractive index of 1.45 [258] matching 
the refractive index of clarified tissues. This is very important for immersion objectives, even 
though in this work images were taken with a dry objective). At the end, samples were placed into 
30 mm MatTeK Botton Glass (MATTEK corporation Massachusetts USA), and covered with 60% 
TDE solution for imaging. Images were obtained with a Leica SP5 Confocal Microscope using a 
Leica dry objective N PLAN 10X/0.25, illuminated with a 561 nm dioded-pumped solid state 
laser using hybrid (HyD) detector. Images were collected using Leica LAS 4.0 image collection 
software and 3D reconstruction and videos were made using IMARIS software.  
Statistical analysis.  
The data are presented as the mean ± standard error of the mean (SEM) for all the studies. 
ANOVA followed by Bonferroni’s post hoc test was used when comparing three or more groups 
and two-tailed Student’s t-test was used to compare two groups, according with the conditions of 
normality and homoscedasticity. Shapiro-Wilk normality test and Brown–Forsythe test were used 
to analyze these conditions. In case the assumptions of normality and homoscedasticity were not 
accomplished we used non-parametrical statistic tests; Mann Whitney test to compare two groups 
and Kruskal-Wallis followed by Dunn's post hoc test to compare three or more groups. P value 
of less than 0.05 was considered significant. Additionally, we used a trend test in those 
experiments where we wanted to show changes along the time, P-trend less than 0.05 was 
considered significant.  
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RESULTS 
1. HYPOXIA AND PULMONARY HYPERTENSION: HYPOXIC REGULATION OF TSP1 AND ITS 
EMERGING TOLE IN PULMONARY HYPERTENSION. 
1.01 Hypoxia-mediated induction of pulmonary TSP1 parallels stabilization of HIF2α.  
Previously we showed that chronic hypoxia increases TSP1 expression in the lung [169]. 
Extending these results, we found that WT mice subjected to hypoxia (10% O2) for 7h or 24h 
experience an increase in pulmonary TSP1 mRNA levels concurrent with induction of phd3, a 
known hypoxia sensitive gene [259] (Figure 8). Analysis of TSP1 mRNA levels in tsp1-/- mice 
showed no detectable levels of TSP1 message but demonstrated significant induction of phd3 
under hypoxia (Figure 8). Analysis of protein levels in WT mice under hypoxia demonstrated a 
rapid time-dependent increase in TSP1 that was matched by parallel increase in the levels of 
HIF2α (Figure 9). As expected, tsp1-/- mice lungs showed no evidence of protein post-hypoxia 
(Figure 9).  
 
Figure 8: Hypoxia-mediated induction of TSP1 mRNA in mice lungs. Quantitative RT-Q-PCR analysis 
was performed to determine TSP1 mRNA expression levels in lung samples from WT and tsp1-/- mice 
exposed to normoxia (Nx) or hypoxia (Hp) -10% O2- for the indicated time points. mRNA levels are 
expressed as fold change over WT in normoxic conditions and controlled with β-Actin as the housekeeping 
gene. The hypoxia reporter gene phd3 was analyzed in the same samples as a control of hypoxic stress. 
Statistical analysis between different conditions was made using two-way ANOVA test followed by 
Bonferroni’s post hoc test, * P<0.05, **P<0.01; # P-trend<0.05. Results are expressed as means ± SEM.  
(n=4), ns (not significant).  
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Figure 9: Hypoxia-mediated induction of TSP1 protein in mice lungs. Protein levels in lung samples 
from WT and tsp1-/- mice challenged with normoxia (Nx) or hypoxia (Hp) were detected via Western blot 
probed against TSP1, HIF2α and α-Tubulin as a loading control. Quantification of TSP1 and HIF2α bands 
was done by densitometry and controlled with α-Tubulin. Protein levels are expressed as fold change over 
WT in normoxic conditions. Statistical comparisons between different conditions were made using a 
Kruskal-Wallis followed by Dunn’s post hoc test, * P<0.05. **P<0.01.  # P-trend<0.05. Results are 
expressed as means ± SEM.  (n=4), ns (not significant). 
 
1.02 Hypoxia upregulates TSP1 in pulmonary vascular and non-vascular cells.  
TSP1 is produced and secreted by systemic arterial VSMC [260], fibroblasts and endothelial cells 
[261]. However, it is not known if PASMC cells and PAEC, and pulmonary-derived fibroblasts 
produce TSP1 and whether this process is modulated by changes in oxygen tension. To test this, 
we isolated pulmonary fibroblasts (mFIB) and pulmonary arterial smooth muscle cells 
(mPASMC) harvested from murine (WT and tsp1-/-) lungs and PAs respectively and confirmed 
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their linage by staining with specific markers for SMC, like smooth muscle actin (SMA) and 
calponin 1 (CNN-1) (Figure 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Characterization of mPASMC and mFIB. A. Staining of tunica media explant of murine PA 
and (B) mPASMC and lung derived fibroblast (mFIB) 7 days after extraction. Visualization of DAPI 
(purple), CNN-1 (blue), SMA (green) and F-Actin (red). Cells were grown on fibronectin (5 µg/ml)-coated 
coverslips. Images shown are representative of three experiments. Bars, 50 µm.  
 
Then we challenged them with hypoxia (1% O2) for 24h. Our results demonstrated that hypoxia 
significantly increased TSP1 mRNA levels in mFIB and stimulated a modest but not significant 
increase in mPASMC (Figure 11A). Accordingly, TSP1 protein levels were significantly 
increased in mFIB and mPASMC cell types after a hypoxic challenge (Figure 11B). To more 
precisely define the hypoxic induction of pulmonary TSP1, we employed fluorescent imaging of 
normoxic and hypoxic cells. Immunofluorescence imaging confirmed increased TSP1 levels in 
hypoxic mFIB and mPASMC that was localized to the peri-nuclear cytoplasm (Figure11C). The 
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same set of experiments were performed in human pulmonary endothelial cells (hPAEC). TSP1 
mRNA and protein levels were upregulated under hypoxic conditions and the same peri-nuclear 
cytoplasm staining of TSP1 was found (Figure 12). 
 
 
 
 
 
 
 
 
 
 
Figure 11: Hypoxia upregulates TSP1 in mouse pulmonary vascular and non-vascular cells. A. mFIB 
and mPASMC from WT were exposed to normoxia (Nx) or hypoxia (Hp) -1% O2- for 24 h and changes 
in mRNA levels determined by RT-Q-PCR. TSP1 mRNA levels are expressed as fold change over 
normoxic conditions and controlled with β-Actin as the housekeeping gene. Average ± SEM of n=3 
performed is shown. * p<0.05. Student´s T-test, ns (not significant). B. Protein levels from mFIB, and 
mPASMC exposed to normoxia (Nx) or hypoxia (Hp) -1% O2- for 24 h were detected by Western blot 
probed against TSP1, HIF2α and α-Tubulin as a loading control. Densitometric analysis was performed to 
quantify TSP1 bands and levels were controlled with α-Tubulin and expressed as fold change over Nx. 
Average ± SEM of n=3 performed is shown. * p<0.05. Student´s T-test, ns (not significant). C. 
Visualization of TSP1 (green) and F-Actin (red) in mFIB, mPASMC grown on fibronectin (5 µg/ml)-coated 
coverslips. Images shown are representative of three experiments. Bars, 50 µm.  
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Figure 12: Hypoxia upregulates TSP1 in human hPAEC. A. hPAEC were exposed to normoxia (Nx) or 
hypoxia (Hp) -1% O2- for 24 h and changes in mRNA levels determined by RT-Q-PCR. TSP1 mRNA 
levels are expressed as fold change over normoxic conditions and controlled with β-Actin as the 
housekeeping gene. Average ± SEM of n=3 performed is shown. * p<0.05. Student´s T-test, ns (not 
significant). B. Protein levels from hPAEC exposed to normoxia (Nx) or hypoxia (Hp) -1% O2- for 24 h 
were detected by Western blot probed against TSP1, HIF2α and α-Tubulin as a loading control. 
Densitometric analysis was performed to quantify TSP1 bands and levels were controlled with α-Tubulin 
and expressed as fold change over Nx. Average ± SEM of n=3 performed is shown. * p<0.05. Student´s T-
test, ns (not significant). C. Visualization of TSP1 (green) and F-Actin (red) in hPAEC grown on fibronectin 
(5 µg/ml)-coated coverslips. Images shown are representative of three experiments. Bars, 50 µm.  
 
1.03 HIF2α regulates TSP1 levels in mouse lung.  
From the above studies, it was apparent that hypoxia rapidly upregulated TSP1 transcript in the 
lung. Nonetheless, it remained unknown at what level HIF controlled TSP1 expression. Since 
both HIF1α and HIF2α null mice are resistant to pulmonary hypertension [160, 161] as well as 
the tsp1-/- mice [169, 190], we wondered whether HIFα activation was sufficient to produce TSP1 
induction in the lung. To this aim we generated mice deficient in the von Hippel Lindau protein 
(VHL). Mice lacking the VHL gene (vhl-/-) no longer process HIFα protein for degradation under 
normoxia [63, 248], and therefore phenocopy hypoxic WT mice. Pulmonary TSP1 mRNA and 
protein levels in normoxic vhl-/- mice were significantly increased compared to the levels in 
normoxic WT mice (Figures 13A, B). To assess whether HIF1α or HIF2α were required for 
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hypoxia-mediated induction of pulmonary TSP1 we generated mice in which both VHL and 
HIF2α or VHL and HIF1α were simultaneously inactivated (vhl-/-/hif2α-/-, vhl-/-/hif1α-/- 
respectively) and analyzed pulmonary TSP1 levels. In contrast to the induction observed in vhl-/- 
mice, pulmonary TSP1 mRNA and protein levels in vhl-/-/hif2α-/- double knockout mice were 
decreased (Figures 13A, B), while in vhl-/-/hif1α-/- TSP1 mRNA levels remained induced (Figure 
6A). To confirm the role of HIF2α in regulating pulmonary TSP1, we exposed hif2α-/- mice to 
chronic hypoxia. As in double knockout mice, hypoxia did not upregulate pulmonary TSP1 in 
hif2α-/- mice (Figure 13B).  
Figure 13: HIF2α regulates TSP1 levels in the mice lung. A. Quantitative RT-Q-PCR analysis was 
performed to determine TSP1 mRNA expression levels in lung samples from WT, VHL deficient (vhl-/-), 
VHL/HIF2α (vhl-/-/hif2α-/-) and VHL/HIF1α (vhl-/-/hif1α-/-) double deficient mice. mRNA levels are 
expressed as fold change over WT and controlled with β-Actin as the housekeeping gene. Average ± SEM 
of n=4 performed is shown.  Statistical comparisons between different conditions were made using Kruskal-
Wallis followed by a Dunn’s post hoc test, * P<0.05, ns (not significant). B. Protein levels in lung samples 
from WT, vhl-/-, vhl-/-/hif2α-/- and hif2α-/- mice under normoxia (Nx) or hypoxia (Hp) -10% O2- for 3 days 
were analyzed by Western blot. Representative images of three experiments are shown. 
 
To further extend these results to human lung, we analyzed TSP1 levels in hPAEC following 
HIF1α or HIF2α interference. Interestingly, hypoxia-mediated induction of TSP1 mRNA was 
downregulated in hPAEC treated with the HIF2α siRNA (Figure 14). When protein levels were 
analyzed in hPAEC, we observed no increase in TSP1 levels in hypoxia following HIF2α 
suppression (Figure 14). 
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Figure 14: HIF2α regulates TSP1 levels in hPAEC.  Protein and mRNA levels of TSP1, HIF1α, HIF2α 
from hPAEC untreated or transfected with scrambled (Scr), HIF1α or HIF2α siRNA and then exposed to 
Nx or Hp -1% O2- for 24h. Western blot is controlled with α-Tubulin. Representative images of four 
experiments are shown. mRNA expression levels are expressed as fold change over normoxic conditions 
and controlled with β-Actin as the housekeeping gene. Average ± SEM of n=4 performed is shown. 
Statistical comparisons between different conditions were made using two-way ANOVA followed 
Bonferroni´s post hoc test, * P<0.05 was considered significant. n=4. ns (not significant). 
 
1.04 TSP1 protein levels are increased in PAs of PAH-patients. 
 
Extending cell and animal studies, we performed Western blot analysis of 5th order PAs from 
individuals with (n=15) and without PAH (n=8). Paralleling results obtained in mice, we found 
upregulation of pulmonary TSP1 protein in PA samples from PAH compared to non-PAH 
individuals. Interestingly though, HIF2α as well as HIF1α protein levels were increased in PA 
samples from PAH (Figure 15).  
Figure 15: Analysis of TSP1 levels in PAs of PAH-patients. Western blot analysis of lysates of 5th order 
PAs from non-PAH and PAH human lungs was performed against TSP1, HIF1α, HIF2α and α-Tubulin as 
loading control. Representative blots and densitometry (average ± SEM) are presented as the mean ratio of 
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target protein to α-Tubulin respectively (n=8 normal and 15 PAH samples), Mann-Whitney test corrected 
by Bonferroni´s post hoc test was performed, * p<0.05. 
 
1.05 The proximal promoter region of tsp1 contains functional Hypoxia Response Elements (HREs).  
We analyzed the proximal promoter region of tsp1and identified two putative HREs between 
positions -1120 to -1196 (site 1) and -249 to -225 (site 2) relative to the transcription starting site. 
These sites contained the core RCGTG/C sequence and were selected based on the highest score 
corresponding to potential HRE sites published in the literature [262]. Further, these sites 
corresponded with open chromatin and transcription factors binding site clusters that are highly 
conserved among different mammalian species (Figure 16).  
 
 
 
 
 
 
 
 
Figure 16: Localization of HREs in the proximal promoter sequence of tsp1. Blast sequence alignment 
of the tsp1 proximal promoter sequence of different mammalian species containing conserved HRE sites 
(Site 1 and Site 2), boxes mark core sequences of HRE sites. 
 
To establish a possible direct interaction of HIF with these putative tsp1 HRE regulatory sites, we 
performed luciferase reporter assays. We inserted tsp1 HRE site 1 or HRE site 2 with three copies 
in tandem in the luciferase reporter plasmid pGL4.23. CHO.K1 cells were co-transfected with 
these HREs and the constitutive active forms of HIF1α or HIF2α, (HIF1α (P-A)2 or HIF2α (P-A)2 
respectively) [193]. Reporter activity demonstrated a HIF2α-mediated significant induction (4- 
and 18-fold in HRE site 1 and HRE site 2 respectively) (Figure 17A). These results clearly 
indicate that HIF2α interacts with both HRE, and on the other hand this interaction reports 
functional activity. It is worth mentioning that HIF2α displayed a higher reporter activity on tsp1 
HRE site 2 compared to HRE site 1. To validate these vectors, we employed as a control the 
luciferase vector p3EGR.Luc bearing a well know functional HRE of VEGF [251] (Figure 17B). 
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Figure 17: HIF2α functionally binds to HREs of the tsp1 proximal promoter sequence. A. Luciferase 
reporter activity assay of tsp1 HREs. Equal numbers of CHO.K1 cells were plated in 24 wells plate (5x105 
cells per well) and co-transfected with PGL4.23-3xHRE1 (HRE site 1) or PGL4.23-3xHRE2 (HRE site 2) 
and with pRV-GFP-HIF1α(P-A)2 (HIF1α(P-A)*2) or pRV-GFP-HIF2α(P-A)2 (HIF2α(P-A)*2) or pRV-
GFP empty vector as control. pRL-SV40 (Renilla) was included in all transfections as a luciferase internal 
control. 24 hours after co-transfection cells were lysed and analyzed for luciferase activity. Results are 
expressed as means ± SEM of relative light units (RLU) normalized to control. Statistical comparisons 
between different conditions were made using Kruskal-Wallis, followed by a Dunn’s post hoc test, 
**P<0.01, ***P<0.001, n=8. B. HIF1α and HIF2α functionally binds to hypoxia response elements of the 
VEGF promoter. Luciferase reporter activity assay of VEGF HRE. CHO.K1 cells were seeded into a 24 
wells plate at equal cell number (5x105 cells per well) and co-transfected with p3EGRLuc-9xHRE.VEGF 
and with pRV-GFP-HIF1α(P-A)2 (HIF1α(P-A)*2) or pRV-GFP-HIF2α(P-A)2 (HIF2α(P-A)*2) or pRV-
GFP-HIF1α(P-A)2bHLH (HIF1α(P-A)*2bHLH), the latest with an additional mutation that inhibits its 
transcriptional activity, or pRV-GFP empty vector as control. pRL-SV40 (Renilla) was included in all 
transfections as a luciferase internal control. Luciferase activity was analyzed 24 hours after co-transfection. 
Results are expressed as means ± SEM of relative light units (RLU) normalized to control. n=3. 
 
1.06 TSP1 stimulates de-adhesion to promote hypoxia-mediated migration of pulmonary-derived 
fibroblasts and PASMC.  
In pulmonary vasculature activation, subsequent migration of fibroblasts and myofibroblasts into 
the medial layer of vessels have been suggested to contribute to vessel remodeling [263, 264]. 
Although TSP1 is known to promote migration of cells under normoxia [265, 266], it is unknown 
if TSP1 controls the migratory activity of mFIB and mPASMC under either normoxia or hypoxia. 
To assess this, we tested in vitro cell migration with the classic transwell assay. mFIB and 
mPASMC harvested from WT and tsp1-/- mice were incubated under normoxia or hypoxia (1% 
O2) for 7 h and migration determined. In response to normoxia both WT and tsp1-/- mPASMC 
and mFIB displayed similar migratory capacity (Figures 18). In contrast, under hypoxic 
conditions WT mFIB displayed significantly greater migratory response compared to tsp1-/- cells 
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Also, hypoxia increased migration in mPASMC from WT but not from tsp1-/- mice (Figure 18).  
Figure 18: Analisis of TSP1 effects on migration of mFIB and mPASMC. Migration of mFIB (A) and 
mPASMC (B) from WT and tsp1-/- mice was assessed in transwell assays. Cells (12 x 103 cells/well) were 
serum-starved for 3 h and then allowed to migrate for 7 h at 37ºC and 5% CO2 under normoxia (Nx) or 
hypoxia (Hp) -1% O2-. As chemoattractant, DMEM with 20% FBS was added into the lower chamber, and 
basal media was used as a negative control. Number of cells migrated are represented as fold ± SEM over 
WT under normoxic conditions. Statistical comparisons between different conditions were made using a 
Kruskal-Wallis followed by Dunn’s post hoc test, * P<0.05. was considered significant, n=4, ns (not 
significant).  
 
Focal adhesion (FA) disassembly promotes cell motility [267]. Interestingly TSP1 is an 
intermediate of cell adhesion and stimulates disassembly of FA contacts [268, 269]. Consistent 
with this, hypoxic WT mFIB and mPASMC exhibited reduced adhesion to fibronectin substrate, 
which correlated with a decrease in FA contacts, compared to cells from tsp1-/- mice (Figure 19).  
Figure 19: Effect of TSP1 on the adhesive capacity of mFIB and mPASMC. Visualization of cell 
adhesion plaques. mFIB and mPASMC grown on fibronectin (5 µg/ml)-coated coverslips were cultured 
under normoxia or hypoxia (1% O2) for 24 h, then fixed, permeabilized and incubated with monoclonal 
antibody to Vinculin (VCL), visualized with Alexa 488 (green), together with phalloidin 568 (red) to stain 
actin filaments (F-Actin). Images shown are representative of three experiments and at least 30 cells per 
condition. Bars, 50 µm.  
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Quantification of the percentage of total FA contacts per cell area, the average area of an 
individual FA contacts and the number of FA contacts per cell area, all demonstrated decreased 
adhesiveness of WT mFIB and mPASMC under hypoxic conditions, consistent with their 
demonstrated increased migratory capacity (Table 5).  
 
Table 5: FAs quantification of  WT and tsp1-/- mFIB and mPASMC under normoxia and 
hypoxia (Corresponding to Figure 19). 
 Total % of FAs/cell area Mean FA area (µm2) FAs/cell area (µm2) 
mFIB 
 
   
wt Nx 19,95 ± 1,57 7,06 ± 0,30 2,61 x 10-2 ± 2,99 x 10-3 
wt Hp 13,36 ± 1,23 5,94 ± 0,24 2,00 x 10-2 ± 1,69 x 10-3 
tsp1-/- Nx 22,90 ± 1,84 7,36 ± 0,29 3,46 x 10-2 ± 2,37 x 10-3 
tsp1-/- Hp 22,55 ± 1,51 * 7,48 ± 0,31 * 3,13 x 10-2 ± 2,02 x 10-3 * 
 
mPASMC 
 
   
wt Nx 18,75 ± 1,65 6,64 ± 0,23 2,86 x 10-2 ± 1,88 x 10-3 
wt Hp 15,29 ± 1,20 5,87 ± 0,16 2,53 x 10-2 ± 1,55 x 10-3 
tsp1-/- Nx 22,05 ± 1,30 7,20 ± 0,17 3,04 x 10-2 ± 1,37 x 10-3 
tsp1-/- Hp 24,91 ± 1,60 * 7,17 ± 0,17 * 3,45 x 10-2 ± 1,79 x 10-3 * 
The data are presented as average ± SEM. Total % of FAs/cell area = Sum of all FAs area in one cell 
divided by the total area of the cell. Mean FA area = Area of a single FA. FAs/cell area = Number of FAs 
in one cell divided by the total area of the cell. Number of experiments = 3. Number of cell analysed = 50-
60 per treatment condition, number of FAs analysed = 400-1500 per cell. Two-way ANOVA followed by 
Bonferroni´s test was used. * Significance vs. WT Hp, P<0.001. 
 
1.07 Hypoxia-mediated increase of TSP1 destabilizes PAEC junctions and increases paracellular 
permeability. 
The above results indicated that TSP1 induces FA disassembly in mFIB and mPASMC. Related 
to this prior, reports have shown that TSP1 also regulates intercellular junctions in PAEC [270]. 
Junctions between endothelial cells are essential for the correct function of the endothelium, 
which has two main roles; shield the underlying vascular layers from the blood, and receive and 
send cell signaling. The resulting loss of endothelial barrier integrity may provide a surreptitious 
avenue for proliferative mediators to come in direct contact with the subendothelium, leading to 
cell proliferation in the medial and adventitial vascular layers [271]. Moreover, after the initial 
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damage, endothelial cells start to growth abnormally by monoclonal endothelial expansion 
creating the plexiform lesions, this contributing to endothelial dysfunction. [146]. Therefore, we 
aimed to determine whether the hypoxia-mediated induction of TSP1 could also influence 
endothelial cell function. To this aim we transfected hPAEC with a control or siRNA against 
TSP1 and then cultured them in normoxia or hypoxia and conducted permeability studies in the 
absence or presence of exogenous TSP1.  
 
 
Figure 20: TSP1 silencing in hPAEC. hPAEC were untreated or transfected with scrambled (Scr) or 
specific TSP1 siRNA (siTSP1) and 24h after transfection cells were exposed to normoxia (Nx) or hypoxia 
(Hp) -1% O2-. mRNA and protein levels of TSP1. mRNA expression levels are expressed over normoxic 
conditions and controlled with β-Actin as the housekeeping gene. Average ± SEM of n=4 performed is 
shown. Statistical comparisons between different conditions were made using two-way ANOVA test 
followed by Bonferroni’s post hoc test, * P<0.05, **P<0.01. n=4. ns (not significant). Western blot is 
controlled with α-Tubulin. Representative images of four experiments are shown. 
 
As predicted, hPAEC treated with the TSP1 targeting siRNA demonstrated significantly less 
TSP1 protein following hypoxia compared to cells treated with the scrambled control siRNA or 
untreated cells (Figure 20). Interestingly, hypoxia and exogenous TSP1 (20 µg/mL) both 
increased cell permeability.  Conversely, knock down of TSP1 blocked the hypoxic-mediated 
increase in cell permeability (Figure 21A). To test the accuracy of our permeability assays we 
used hPAEC treated with 1mM EGTA as a control. As expected we observed an increase on 
permeability after the treatment (Figure 21B). To inquire if this was due to changes in intercellular 
junctions we performed immunofluorescent staining of an essential constituent of tight junctions, 
the protein Zonulin-1 (ZO-1) in these cells. Interestingly, hPAEC transfected with the control 
siRNA under hypoxia displayed an irregular immunofluorescent staining pattern of ZO-1 
distribution. However, treating the cells with a TSP1 siRNA ameliorated the hypoxia-mediated 
dysregulation of ZO-1 (Figure 22).   
 
RESULTS 
 
 
73 
Figure 21: Hypoxia-mediated increase in TSP1 increases paracellular permeability in hPAEC. A. 
Confluent hPAEC monolayers transfected with scrambled (scr) or specific TSP1 siRNA (siTSP1) were 
exposed to normoxia (Nx) or hypoxia (Hp) -1% O2- or treated with TSP1 exogenous (20 ug/ml) for 7h, and 
flux of FITC-dextran 70kDa (FD-70) across hPAEC monolayers was assessed for 1h. B. Permeability 
control. Confluent hPAEC monolayers were exposed to EGTA (1mM) for 2 minutes and flux of FITC-
dextran 70kDa across hPAEC monolayers for 1h. (A,B) Fluorescence was quantified with a 
spectrophotometer at 515 nm. Average ± SEM of n=6 performed is shown. Statistical comparisons between 
different conditions were made using two-way ANOVA test followed by Bonferroni’s post hoc test, * 
P<0.05, **P<0.01, ***P<0.001.  ns (not significant), (AU) arbitrary units. 
 
Figure 22: Hypoxia-mediated increase in TSP1 destabilizes hPAEC junctions. Immunofluorescence 
analysis of ZO-1-Alexa 488 (green) and phalloidin 568 (red) to visualize actin filaments (F-Actin) in 
hPAEC transfected with scrambled (Scr) or specific TSP1 siRNA (siTSP1). Two days after transfection 
cells were grown on fibronectin (2 µg/ml)-coated coverslips and cultured under normoxia (Nx) or hypoxia 
(Hp) -1% O2- for 24 h. Images shown are representative of three experiments. Bars, 50 µm. 
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1.08 Hypoxia-mediated increase of TSP1 promotes human PA fibroblast (hPAFIB) differentiation into 
myofibroblast.  
PAFIB contribute to PA remodeling through differentiation into SMC-like phenotype cells, 
known as myofibroblasts [147, 148]. PAFIB grow and differentiate into myofibroblasts under 
hypoxic or stress conditions [272], contributing to the tunica media hyperplasia. PAFIB also 
acquire a contractile phenotype [273], and therefore, aggravate the PAH vasocontraction [274]. 
Such differentiation drives effective wound healing and is largely regulated by the TGF-β, which 
on the other hand is a well-known activating target of TSP1 [275, 276]. Therefore, we 
hypothesized that hypoxia-mediated increase in TSP1 activates latent TGF-β, which in turn 
triggers PAFIB differentiation. To asses this, we exposed undifferentiated hPAFIB to normoxia 
or hypoxia alone or in combination with a TSP1 inhibitor (LSKL) or a TGF-β inhibitor (SB 
431542) and then observed the number of appearing smooth muscle actin fibers, a stablished 
smooth muscle cells marker. After four days, we saw that hypoxia clearly increased the number 
of SMA fibers and that LSKL and SB 431542 treatment abolished this phenomenon (Figure 23).  
 
 
Figure 23: Effect of hypoxia-mediated increase of TSP1 levels in the recruitment of SMA in F-Actin 
filaments in hPAFIB. Immunofluorescence of hPAFIB with SMA-cy3 (green) and phalloidin 568 (red) to 
visualize actin filaments (F-Actin). Cells at passage 5 were grown on fibronectin (2 µg/ml)-coated 
coverslips and treated with TSP1 inhibitor, LSKL (1µM) or TGFβ inhibitor, SB 431542 (10µM), tagged as 
SB. Afterwards cells were cultured under normoxia (Nx) or hypoxia (Hp) -1% O2- for 4 days. Images 
shown are representative of three experiments. Bars, 50 µm.  
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1.09 TSP1 limits hypoxia-mediated vascular responses in PAs.  
Vascular contraction and dilation are oxygen sensitive processes that deteriorate under hypoxic 
conditions [277]. In vivo, hypoxia promotes vasodilation of the systemic circulation and increased 
tissue perfusion [278], whereas in the pulmonary circulation acute hypoxia promotes 
vasoconstriction to increase perfusion of parenchyma that is less ventilated [279]. Previous 
studies have reported that under normoxia, systemic arterial blood flow in skeletal muscles and 
perfusion of skin flaps is limited by TSP1 basally, and in response to ischemia reperfusion injury 
[185, 260, 280, 281]. However, it was not clear if endogenous TSP1 limited pulmonary arterial 
function under hypoxia. To investigate this, we challenged PA from male WT and tsp1-/- mice to 
sodium nitroprusside (SNP), a pro-drug metabolized by smooth muscle cells to nitric oxide (NO), 
or acetylcholine (Ach), an endothelial cell activator and stimulator of endogenous NO production, 
and assessed vasodilation under both normoxia and hypoxia (1% O2). We observed that 
vasodilation induced by SNP under normoxic or hypoxic conditions was similar among WT and 
tsp1-/- PA (Figure 24).  
 
 
Figure 24: Effect of hypoxia on SNP-induced relaxation in mice PAs. Vascular response to SNP was 
analyzed in (5-HT)-stimulated endothelium-intact PAs from WT or tsp1-/- mice previously incubated for 
16 hours under normoxic (Nx) or hypoxic (Hp) -1% O2- conditions. Statistical comparisons were made 
using two-way ANOVA, followed by Bonferroni’s post hoc test. Results are expressed as means ± SEM 
(% relaxation), (n=10). 
 
Similarly, under normoxia WT and tsp1-/- PAs displayed comparable sensitivity to Ach (Figures 
25). However, endothelium-dependent vasodilation induced with Ach was significantly reduced 
in hypoxic WT PA. In contrast, hypoxic tsp1-/- PA maintained Ach sensitivity comparable to 
normoxic vessels (Figures 25). 
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Figure 25: Effect of hypoxia on ACh-induced relaxation in mice PAs Vascular response to ACh was 
analyzed in (5-HT)-stimulated endothelium-intact PAs from WT or tsp1-/- mice previously incubated for 
16 hours under normoxic (Nx) or hypoxic (Hp) -1% O2- conditions. Statistical comparisons were made 
using two-way ANOVA, followed by Bonferroni’s post hoc test, * P<0.05, **P<0.01. Results are expressed 
as means ± SEM (% relaxation), (n=10). 
 
TSP1 affects hypoxia-mediated dowregulation of Kv1.5. It is reported that hypoxia inhibits the 
function and expression of several Kv channels in PASMC, which results in membrane 
depolarization and leads to an increase in intracellular Ca2+ concentrations [282]. Therefore, we 
tested the role of TSP1 on the modulatory effect of hypoxia on Kv channels and whether this 
affected intracellular calcium concentration. We analyzed the contractile responses induced by 
Kv1.5 or Kv7 channel inhibitors in PA from WT or tsp1-/- mice exposed to normoxia or hypoxia. 
We found that the Kv7 channel inhibitor XE991 produced a similar degree of contraction under 
normoxia and hypoxia in both, WT and tsp1-/- PA (Figure 26A). Conversely, contraction mediated 
by the Kv1.5 channel inhibitor DPO1 was markedly diminished in hypoxic, as compared to 
normoxic, WT PA. Remarkably, hypoxic tsp1-/- PA treated with DPO1 had no loss of 
vasoconstriction (Figure 26B).  
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Figure 26: Effect of TSP1 expression on XE991 and DPO1-induced contraction of mice PAs after 
hypoxia. Vascular responses were analyzed in endothelium-intact PAs from WT or tsp1-/- mice previously 
incubated for 16 hours under normoxic (Nx) or hypoxic (Hp) -1% O2- conditions. Average values of the 
contraction induced by XE991 (0.3 µmol/L) (A) and DPO1 (1 µmol/L) (B), Kv7 and Kv1.5 channels 
inhibitors respectively. Statistical comparisons were made using two-way ANOVA, followed by 
Bonferroni’s post hoc test, * P<0.05, ns (not significant). Results are expressed as means ± SEM (% 
contraction), (n=10). 
 
Since we observed a lower response to DPO1 in WT PAs under hypoxia, next, we analyzed the 
effects of this drug on intracellular Ca2+ levels. In agreement with the data in Figure 26, the 
increase in intracellular Ca2+ induced by DPO1 was attenuated in hypoxic as compared to 
normoxic WT mPASMC. Of note, this difference was not observed in tsp1-/- mPASMC (Figure 
27A). mPASMC treated with ionomycin, a calcium ionophore, were used as controls (Figure 
27B). 
 
Figure 27: Life cell DPO1-induced calcium measurement in mPASMC. Life cell calcium measurement 
with cytosolic calcium probe Fluo-4 AM. A. Average values of DPO1-induced fluorescence (2 µmol/L) in 
mPASMC from WT or tsp1-/- mice previously incuated for 16 hours under normoxic (Nx) or hypoxic (Hp) 
-1% O2- conditions. B. Intracellular calcium control: Average values of the ionomycin-induced 
fluorescence (1 µmol/L) in mPASMC from WT or tsp1-/- mice. Untreated (Unt), treated with ionomycin 
(Iono). Statistical comparisons were made using two-way ANOVA, followed by Bonferroni’s post hoc test; 
* P<0.05, ***P<0.001, ns (not significant). Results are expressed as means ± SEM, (DPO1 n=10, 
Ionomycin n=4). AU (arbitrary units).  
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To assess if these effects were due to changes on Kv1.5 expression, we analyzed Kv1.5 mRNA 
levels in mPASMC under hypoxia. We observed that hypoxia significantly decreased Kv1.5 
mRNA levels in mPASMC harvested from lungs of WT mice. Conversely hypoxia did not alter 
Kv1.5 mRNA levels in cells from tsp1-/- mice (Figure 28). 
 
 
 
 
 
 
Figure 28 TSP1 null mPASMC are protected from hypoxia-induced inhibition of Kv1.5 mRNA. 
Quantitative RT-Q-PCR analysis was performed to determine Kv1.5 mRNA expression levels in mPASMC 
from WT or tsp1-/- mice under normoxia (Nx) or hypoxia (Hp) -1% O2- for 24 h. mRNA levels are expressed 
as fold change over WT in normoxic conditions and controlled with β-Actin as the housekeeping gene. 
Results are expressed as means ± SEM. Statistical comparisons between different conditions were made 
using a mouse type stratified Student´s T-test, * P<0.05, n=3.  
 
1.10 Implementation of 3D imaging CLARITY technique in mice lungs.  
 
Our previous results gave us new insights into the molecular mechanisms that regulate TSP1 in 
hypoxic lungs. They also reveal the possible role of hypoxia in the control of cellular functions 
relevant to PAH. However, there is an important need to understand in detail the structural 
changes that occur in the lung during this pathology. As we traverse from molecular mechanisms 
to cellular events, it is crucial to illuminate PAH events at the organ scale. Although 
immunohistochemistry and immunofluorescence techniques could give us some relevant 
information about what is happening in the lung architecture under pathologic conditions, these 
approaches are limited and do not allow us to appreciate changes that affect the integrity or 
cellular compartmentalization in the whole lung. We aimed to understand the structure-function 
relationship at cellular and organ level produced under hypoxia using new imaging techniques as 
CLARITY. It is an innovative technological advance in which intact biological tissue is 
transformed into a nanoporous hydrogel-hybridized form with markedly improved chemical and 
optical accessibility [283-285]. With this powerful tool, we can obtain high-resolution structural 
data in a 3D reconstruction of the organ that allows us to study structural changes at cellular level 
in situ giving us a new perspective of the disease without disrupting tissue cytoarchitecture. We 
can analyze the general lung structure, bronchus, alveoli and the vasculature zooming in to the 
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cell and /or organelles level. We performed CLARITY of WT and tsp1-/- mice lungs of males 
exposed to normoxia or hypoxia plus sugen 5416 for 3 weeks following a simplified passive 
CLARITY protocol from Dr Rinaman [257]. After clarifying process, we performed staining with 
SMA to validate the technique. In Figure 29, we show a 3D image of WT mice lung staining 
where it can be appreciated SMA staining in big PAs and main bronchus. Although these results 
demonstrate that CLARITY can be performed in mice lungs, there is still room for improvement.  
 
Figure 29: SMA staining in clarified mouse lungs. Images depict a 400 µm z-stack 3D reconstruction of 
adult (3 months) WT mouse lungs clarified by passive CLARITY and stained for α-SMA with Alexa 488 
(green). Big PAs and main bronchus can be appreciated. Scale bar indicates the image size.  
 
Next, we analyzed TSP1 staining in male WT and tsp1-/- exposed to normoxia or hypoxia plus 
sugen 5416 for 3 weeks (Figure 30). We observed that in lungs from WT mice under hypoxia 
plus sugen 5416 TSP1 staining appears in clusters through the whole parenchyma. Multiple 
staining with other cell specific markers will allow us to determine the source of TSP1 in the 
lungs and which cell type is contributing more to increase TSP1 levels under hypoxia or in PAH. 
At this point we are still working on improving the resolution of our images.   
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Figure 30: TSP1 staining in clarified mouse lungs under Hp/Sugen treatment. A. Visualization of 
TSP1 in adults (3 month) mouse lungs of male WT and tsp1-/- exposed to normoxia (Nx) or hypoxia (10%) 
plus sugen 5416 (Hp+Su) for 3 weeks. Mice lung were clarified by passive CLARITY and stained with 
TSP1 with Alexa 488 (fire). Representative images are shown (n=3). B. Images depict a 400 µm z-stack 
3D reconstruction. Scale bars indicate image size in each frame.  
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2. HYPOXIA AND CANCER: IMPACT OF HYPOXIA AND VHL LOSS ON THE REGULATION OF 
VCAM-1 AND ITS FUNCTIONAL EFFECTS ON THE IMMUNE EVASION OF RCC                
  
2.01 VHL loss and hypoxia regulate VCAM-1 levels in ccRCC cells. 
Although previous studies have suggested the significance of VCAM-1 levels in renal 
carcinomas, little is known about the mechanisms that regulate this adhesion molecule in ccRCC. 
We aim to study whether VHL loss, the most characteristic event occurring in these tumors, 
affected VCAM-1 expression. To this aim we first analyzed VCAM-1 mRNA and protein 
expression levels in ccRCC cell lines that expressed a non-functional or aberrant VHL protein 
(786-O and RCC4), and were stably transfected with empty vector (786-O-pRv, RCC4-pRv) or 
with wild-type VHL (786-O-VHL, RCC4-VHL) respectively; cells that expressed normal VHL 
(Caki-1) and cells with a non-functional mutated VHL (Caki-2). Our results proved that VCAM-
1 mRNA and protein levels were significantly decreased in cells lacking functional VHL (Figures 
31A, B).  
 
Figure 31: Effect of VHL loss and hypoxia on VCAM-1 levels in ccRCC cell lines. A. VCAM-1 mRNA 
levels were determined by quantitative RT-Q-PCR in 786-O and RCC4 transfected with empty vector pRv 
(786-O-pRv and RCC4-pRv) or with pRv-VHL (786-O-VHL and RCC4-VHL), Caki-1 and Caki-2 exposed 
to normoxia (Nx) or hypoxia 0.5 % O2 (Hp) for 24 h. mRNA levels are expressed as fold change and 
normalized over the levels of VHL positive cells in normoxic conditions and controlled with β-Actin as the 
housekeeping gene. Statistical analysis was made using two-way ANOVA test followed by Bonferroni’s 
post hoc test. The values represent the average ± SEM (n=6) experiments with *P<0.05; **P<0.01; 
***P<0.001 or ****P<0.0001 were considered significant; ns (not significant). B. VCAM-1 and VHL 
protein levels were analyzed in total cell lysates from 786-O-pRv, 786-O-VHL, RCC4-pRv, RCC4-VHL, 
Caki-1 and Caki-2 cell lines exposed to normoxia (Nx) or hypoxia 0.5 % O2 (Hp) for 24 h. A representative 
Western blot is shown, n=6. As a loading control α-Tubulin was used.  
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To confirm that this regulation was not a side effect due to the overexpression of VHL we 
analyzed the effect of VHL loss in the ACHN cell line, which express functional VHL, and 
knocked down its expression using siRNA. Our results confirmed that VHL loss significantly 
affected VCAM-1 mRNA levels (Figure 32).  
 
 
Figure 32: Effect of VHL loss and hypoxia on VCAM-1 mRNA levels in the renal adenocarcinoma 
cell line ACHN. VHL and VCAM-1 mRNA levels were determined by quantitative RT-Q-PCR in ACHN 
cells, untreated, transfected with a scrambled siRNA (Scr), or siRNAs specific for VHL, exposed to 
normoxia (Nx) or hypoxia 0.5 % O2 (Hp) for 24 h. Gene expression was represented as the fold change 
against the levels of untreated cells in normoxic conditions and controlled with 𝛽-Actin gene expression 
levels. Statistical analysis was made using one-way ANOVA test followed by Bonferroni’s post hoc test, 
the values represent the average ± SEM (n=4) experiments with *P< 0.05, **P<0.01, were considered 
significant, ns (not significant). 
 
Since hypoxia is considered a hallmark for tumor progression and is associated with disease 
progression and poor prognosis, we also analyzed the effects of hypoxia in the levels of VCAM-
1 in these tumor cells. Similar to VHL loss, hypoxic conditions decreased VCAM-1 mRNA and 
protein levels (Figure 31). Furthermore, the decrease in mRNA levels was observed at the short 
time of 6 h while protein changes were observed after 12 h (Figure 33).  
 
Figure 33: Short time effects of hypoxia on VCAM-1 mRNA and protein levels in 786-O-VHL cell 
line. VCAM-1 mRNA levels were determined by quantitative RT-Q-PCR in 786-O-VHL cells exposed to 
normoxia (Nx) or hypoxia 0.5 % O2 (Hp) for 6, 12 and 24 h. Gene expression was represented as the fold 
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change against the levels of cells in normoxic conditions and controlled with 𝛽-Actin gene expression 
levels. Statistical analysis was made using two-way ANOVA test followed by Bonferroni’s post hoc test, 
the values represent the average ± SEM (n=4) experiments, **P<0.01, ***P<0.001 and ****P<0.0001 were 
considered significant. VCAM-1 protein levels of the same experiment were analyzed. As a loading control 𝛼-Tubulin was used. A representative Western blot is shown, n=3. 
 
Next, we asked whether VCAM-1 decreased mRNA levels were due to transcriptional regulation 
or mediated by post-transcriptional events (e.g., processing, degradation). To this aim we first 
analyzed mRNA stability by treating 786-0-VHL cells with the transcriptional inhibitor 
actinomycin D and then subjected them to normoxia or hypoxia for different times. Our results 
proved that hypoxia did not affect the stability of VCAM-1 mRNA (Figure 34A). To further 
confirm that a transcriptional mechanism was involved we analyzed the heterogeneous nuclear 
RNA (hnRNA), mRNA before splicing modification that proves to be useful to determine gen 
transcriptional state. We found that hnRNA was similarly decreased under hypoxia or in VHL 
negative cells (Figure 34B). Therefore, these data provide support for a transcriptional repression 
of VCAM-1 mediated by VHL loss or hypoxia.  
 
 
Figure 34: Effect of hypoxia and VHL loss on VCAM-1 mRNA stability and hnRNA in ccRCC lines. 
A. 786-O-VHL cells were treated with actinomycin D (2 µg/ml) and then cultured under normoxia or 
hypoxia for the indicated times. Gene expression are represented as fold change and normalized over the 
levels of VHL positive cells in normoxic conditions (considered 100 %) and controlled with β-Actin gene 
expression levels. The values of a representative experiment of n=4 is shown. B. VCAM-1 mRNA levels 
were determined by quantitative RT-Q-PCR before splicing (measuring nuclear heterogeneous RNA, 
hnRNA) in 786-O-pRv, 786-O-VHL, RCC4-pRv and RCC4-VHL exposed to normoxia (Nx) or hypoxia 
0.5 % O2 (Hp) for 24 h. Gene expression was represented as fold change over the levels of VHL positive 
cells in normoxic conditions and controlled with β-Actin as the housekeeping gene. Statistical analysis 
between different conditions was made using two-way ANOVA test followed by Bonferroni’s post hoc 
test, the values represent the average ± SEM (n=4) experiments, ***P<0.001, ****P<0.0001 were 
considered significant, ns (not significant).  
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Since VCAM-1 is a cell membrane protein, we asked whether a decrease in total protein levels 
resulted in decreased expression in the cell membrane. Analysis of VCAM-1 membrane protein 
by flow cytometry revealed a significant decrease in VHL deficient cells compared to their 
counterparts stably transfected with VHL and in VHL positive cells subjected to hypoxic 
conditions compared to normoxia (Figure 35). These results indicated that VHL loss or hypoxia 
affect VCAM-1 exposition in the cell surface which in turn might also have functional effects.  
 
Figure 35: Effect of VHL loss and hypoxia on 
VCAM-1 membrane levels in ccRCC cell 
lines.  VCAM-1 levels at the cell membrane 
were determined by flow cytometry in 786-O-
VHL and 786-O-pRv cells exposed to normoxia 
(Nx) or hypoxia 0.5 % O2  (Hp) for 24 h. 
Quantification of the fluorescence mean in each 
condition is shown. Statistical analysis was 
made using two-way ANOVA test followed by 
Bonferroni’s post hoc test and the values 
represent the average ± SEM (n=4) 
experiments. ***P<0.001 was considered   
significant, ns (not significant). 
 
 
2.02 Transcriptional regulation of VCAM-1 under hypoxia or in the absence of VHL is not  
mediated by HIF.  
VCAM-1 transcriptional regulation in the absence of VHL or in hypoxia suggested that the 
hypoxia inducible factors, HIFs, might be involved in downregulating VCAM-1 in ccRCC cell 
lines. To address this aim, we knockdown their expression by using specific siRNA to HIF1α or 
HIF2α in these cells. HIF2α interference in 786-O cells, which have lost HIF1α expression [194], 
did not prevent the decrease in VCAM-1 mRNA levels in VHL negative cells or in hypoxia 
(Figure 36A, top). However, the expression levels of the HIFα target gene phd3 were significantly 
decreased (Figure36A, bottom). Similar results were observed when VCAM-1 protein levels were 
analyzed in RCC4-VHL cells in which HIF1α or HIF2α had been interfered (Figure 36B).  
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Figure 36: Role of HIFα in VCAM-1 
regulation in ccRCC cell lines. A. VCAM-
1 and phd3 mRNA levels in 786-O-VHL or 
786-pRv cells untreated, transfected with a 
scrambled siRNA (Scr), or siRNAs specific 
for HIF2α (siHIF2α) were analyzed after 24 
h under normoxia (Nx) or hypoxia 0.5 % O2 
(Hp). Gene expression was represented as 
fold change over the levels of VHL positive 
cells in normoxic conditions and controlled 
with β-Actin as the housekeeping gene. 
Statistical analysis was made using two-way 
ANOVA test followed by Bonferroni’s post 
hoc test, the values represent the average ± 
SEM (n=3) experiments, *P<0.05 and 
**P<0.01 were considered significant, ns 
(not significant). B. VCAM-1, HIF1α and 
HIF2α protein levels were analyzed in total 
cell lysates from RCC4-VHL transfected 
with a scrambled siRNA (Scr), or siRNAs 
specific for HIF1α (siHIF1α) or HIF2α 
(siHIF2α) and then subjected to 24 h under 
normoxic (Nx) or hypoxic (0.5 % O2) 
conditions (Hp). A representative Western 
blot is shown, n=3. 
 
 
 
 
Additionally, HIF-independent regulation of VCAM-1 in ccRCC cells was also confirmed in cells 
expressing a mutant form of VHL that has been previously reported to regulate HIF normally but 
is defective in promoting extracellular fibronectin matrix assembly, the naturally occurring type 
2C VHL mutant L188V [286, 287]. Our results demonstrated that VCAM-1 mRNA and protein 
levels in VHL mutant L188V under normoxic or hypoxic conditions were significantly decreased 
to levels resembling those in VHL negative cells (Figures 37A, B). Conversely, mRNA levels of 
a well-known HIF target gene, GLUT-1, were similarly regulated in VHL and VHL mutant 
L188V (Figure 37A). Taken together these data demonstrate that VCAM-1 transcriptional 
regulation in ccRCC cell lines is independent of HIF. 
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Figure 37: Effect of VHL mutation 
L188V in VCAM-1 regulation. A. 
GLUT-1 and VCAM-1 mRNA levels 
were quantified by RT-Q-PCR in 786-
O-VHL, 786-pRv or 786-O-VHL 
(L188V) (cells stably expressing the 
VHL mutant L188V) cultured under 
normoxia (Nx) or hypoxia 0.5 % O2 
(Hp) for 24 h. mRNA levels are 
represented as fold change over the 
levels of VHL positive cells in 
normoxic conditions and controlled 
with β-Actin as the housekeeping gene. 
Statistical analysis was made using two-
way ANOVA test followed by 
Bonferroni’s post hoc test, the values 
represent the average ± SEM (n=4) 
experiments. **P<0.01 was considered 
significant, ns (not significant). B. 
VCAM-1 and VHL protein levels were 
analyzed in total cell lysates of 786-O-
VHL, 786-pRv or 786-O-VHL (L188V) 
cells. As a loading control α-Tubulin 
was used.  A representative Western 
blot is shown, n=3. 
 
 
2.03 VHL and PHDs control VCAM-1 levels in ccRCC cells via NF-κB pathway. 
 It is well established that nuclear factor-kappa B (NF-κB) pathway regulates VCAM-1 
expression [288, 289]. To ascertain how hypoxia or VHL loss affected the NF-κB signaling 
pathway and whether this was involved in VCAM-1 regulation in ccRCC cells, we cultured the 
cells under hypoxia and treated them with the NF-κB agonist TNF-α. Our results proved that 
hypoxia-mediated decrease of VCAM-1 mRNA levels in VHL positive cells were completely 
recovered with TNF-α treatment and those in normoxia were further increased (Figure 38). 
Conversely, TNF-dependent induction of VCAM-1 was lost in the absence of VHL (Figure 38). 
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Figure 38: Effect of TNFα in ccRCC cell lines. VCAM-1 mRNA levels were analyzed in 786-O or RCC4 
positive or negative cells under different stimulus for 24 h: normoxia (Nx) hypoxia 0.5 % O2 (Hp), alone 
or in combination with TNFα (20 ng/ml). Statistical analysis was made using two-way ANOVA test 
followed by Bonferroni’s post hoc test. The values represent the average ± SEM (n=6) experiments, 
***P<0.001 was considered significant, ns (not significant).  
 
To further prove that the NF-κB signaling pathway was involved in keeping high levels of 
VCAM-1 in VHL positive cells, we cultured the cells under hypoxia, with DMOG (a PHD 
inhibitor) and with an inhibitor of the NF-κB pathway (SM7368), alone or in the presence of 
TNF-α. Our results demonstrated that SM7368 treatment decreased significantly VCAM-1 
mRNA and protein levels (Figure 39). Similarly, VCAM-1 levels remained low in cells treated 
with DMOG alone or in combination with TNF-α (Figure 39). These results prompted us to think 
that hypoxic decrease of PHD activity was probably involved in this signaling pathway.  
Figure 39: VHL and PHDs limit VCAM-1 regulation via NF-κB in ccRCC cells. VCAM-1 mRNA 
levels (A, B) and protein (B) were analyzed in 786-O or RCC4 positive cells under different stimulus for 
24 h: normoxia (Nx), hypoxia  0.5 % O2 (Hp), DMOG (1 mM) or SM7368 at 20 µM (SM) alone or in 
combination with TNFα (20 ng/ml). Statistical analysis was made using one-way ANOVA test followed 
by Bonferroni’s post hoc test. The values represent the average ± SEM (n=6) experiments, ***P<0.001 was 
considered significant, ns (not significant). A representative Western blot is shown (n=4). As a loading 
control α-Tubulin was used. 
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To ascertain this, we knocked down the three PHDs, PHD1, PHD2 and PHD3 in our VHL positive 
cells and analyzed VCAM-1 mRNA and protein levels. We observed that VCAM-1 mRNA and 
protein levels were decreased when specific siRNA for PHD1, 2 or 3 were used, although this 
regulation only reached significance when PHD2 or PHD3 were interfered (Figure 33). 
Altogether these results indicated that VHL is an essential component in the NF-κB-mediated 
regulation of VCAM-1 in these cell lines, and that PHDs might be a switch that enables VHL to 
increase VCAM-1 levels. 
 
 
Figure 40: PHDs contributes to maintain VCAM-1 levels in ccRCC cells. A. PHD1, PHD2, PHD3 and 
VCAM-1 mRNA levels in 786-O-VHL cells untreated, transfected with a scrambled siRNA (Scr), or 
siRNAs specific for each PHD (siPHD1, siPHD2 or siPHD3) were analyzed. Gene expression is 
represented as fold change over the levels of untreated cells and controlled with β-Actin as the housekeeping 
gene. Statistical analysis was made using one-way ANOVA test followed by Bonferroni’s post hoc test, 
the values represent the average ± SEM (n=4). *P<0.05 was considered significant. B. VCAM-1 protein 
levels were detected in the same samples and quantification of protein bands controlled with α-Tubulin is 
represented. Protein levels are expressed as fold change over untreated cells. Statistical analysis was made 
using one-way ANOVA test followed by Bonferroni’s post hoc test, the values represent the average ± 
SEM (n=4). *P<0.05, **P<0.01 were considered significant, ns (not significant). A representative Western 
blot is shown, n=3.  
 
2.04 VHL and hypoxia affect non-canonical NF-κB pathways in ccRCC cells.  
Our results above indicated that VCAM-1 repression in ccRCC cells might be due to decreased 
NF-κB signaling in cells lacking VHL or in hypoxia. Conversely, previous results demonstrate 
that VHL loss or hypoxia activates the canonic NF-κB signaling in RCC cell lines [94, 95, 290]. 
To reconcile our results with previously published ones we aimed to analyze if changes on 
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different members of the non-canonical NF-κB pathways were affected in ccRCC cells and these 
could explain the regulation of VCAM-1 in these cells. Interestingly protein levels of central 
signaling components of the non-canonical NF-κB pathway, NIK and its downstream kinase, 
inhibitor of NF-κB kinase α (IKKα), demonstrated a consistent decrease in cells lacking VHL 
(Figure 41). In addition, protein levels of the transcriptional activator complex Rel B-p52 were 
significantly decreased in the absence of VHL or in hypoxic conditions, while protein levels of 
the canonical NF-κB transcription factor p65 (Rel A) remained stable in all conditions (Figure 
41).  
 
Figure 41: Effects of VHL and hypoxia in the non-canonical NF-κB pathway in ccRCC cells. Western 
blot of RCC4 VHL positive or negative cells under normoxia (Nx) or hypoxia  0.5 % O2  (Hp) for 24 h. 
Images show protein levels of VCAM-1, NIK, IKKα, Rel B, p65, p52,  VHL and α-Tubulin as a loading 
control.  A representative Western blot is shown, n=3.  
 
To further confirm that defects on the non-canonical pathway were responsible for the decrease 
on VCAM-1 levels, we knocked down the expression of several components of this pathway in 
VHL positive cells. Our results proved that interference of IKKα, NIK or p52 in VHL positive 
cells resulted in a significant decrease of VCAM-1 levels. Conversely, the interference of the 
canonic component p50 had only minimal effects on VCAM-1 protein levels (Figure 42). These 
results clearly prove that in the absence of VHL or in hypoxia the non-canonical NF-κB pathway 
is affected, and this contributes to the regulation of VCAM-1 in these conditions.  
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Figure 42: Effects of the interference of the non-canonical NF-κB pathway on VCAM-1 levels. 
Western blot of RCC4 VHL positive or negative cells transfected with a scrambled siRNA (Scr), or siRNAs 
specific for IKKα, NIK, p52, p50. Images show protein levels of VCAM-1, NIK, IKKα, p52, p50, and α-
Tubulin as a loading control.  A representative Western blot is shown, n=3.  
 
2.05 TNFα effects on VHL mutant ccRCC cell lines.   
Each tumor sample is a mixture of many different cell types and that they may be expressing 
unique and different VCAM-1 messengers. Furthermore, there is a wide range of VHL mutations 
that determine the tumor's own characteristics as well as the contribution of other factors that may 
be affected and have synergistic or antagonistic effects on gene regulation. Our previous results 
demonstrate the dependence of VHL on the regulation of VCAM-1 in 786-O and RCC4 cells, 
even so we wanted to know whether other VHL mutations could interfere in the TNF-α-mediated 
induction of VCAM-1. To this aim, we used 786-O cells expressing the naturally occurring type 
2C VHL mutant L188V, a non neddylateable version of VHL termed RRR or another version of 
VHL (KRR) which does not interfere with the normal function of VHL. ccRCC cells were treated 
with TNF-α for 24 h and VCAM-1 protein and mRNA levels were analyzed (Figure 43), Our 
results demonstrated that each VHL mutation had different sensibilities for TNF-α-mediated 
induction of VCAM-1. Of note, 786-O-RRR cells had low basal levels of VCAM-1, although it 
preserved sensibility to TNF-α treatment. In addition, these results proved to be interesting in that 
different VHL mutations affected VCAM-1 levels and regulation differently. 
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Figure 43: Analysis of VCAM-1 
levels in VHL mutants. VCAM-1 
mRNA and protein levels were 
determined in 786-O transfected 
with empty vector pRv (786-O-
pRv), with pRv-VHL (786-O-
VHL) or with type 2C mutants 
L188V (786-O-188), RRR (786-O-
RRR) and its control KRR (786-O-
KRR). Statistical analysis was 
made using two-ways ANOVA test 
followed by Bonferroni’s post hoc 
test. The values represent the 
average ± SEM (n=6) experiments, 
*P<0.05 and ****P<0.0001 were 
considered significant. A 
representative Western blot of n=4 
is shown. As a loading control α-
Tubulin levels were analyzed. 
 
2.06 VHL and PHDs control VCAM-1 levels in human umbilical vein endothelial cells (HUVECS).  
VCAM-1 is very relevant in activated endothelium specially in the context of tumor migration 
and immune cell trafficking. Several reports in the literature have investigated the effects of 
hypoxia and/or TNF-α on endothelial VCAM-1 levels, however those studies prove a lack of 
consensus in the pattern of regulation. Some of them report a hypoxia-mediated increase on 
VCAM-1 levels [291, 292] while others observe a decrease on endothelial VCAM-1 mRNA and 
protein levels under hypoxic conditions [293]. Since the studies were performed with different 
endothelial cell types, we believe that the differences observed are due to a cell type dependent 
regulation. Although those studies analyzed the effects of hypoxia on VCAM-1 levels, none of 
them tested the effects of VHL loss in the levels of endothelial VCAM-1. Therefore, we tested 
the effects of hypoxia and VHL loss on VCAM-1 levels in HUVEC. We found that TNF-α-
induced VCAM-1 levels were significantly decreased in HUVEC treated under hypoxia, or 
treated with PHD or NF-𝜅B inhibitors (Figure 44A), as well as in cells treated with VHL siRNA 
(Figure 44B). Therefore, these results clearly prove that a VHL/and or hypoxia-dependent 
regulation of VCAM-1 is not unique to ccRCC, but it can also be extended to not tumoral cells. 
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Figure 44: Effect of VHL loss, hypoxia and NF-κB inhibitors on VCAM-1 levels in HUVEC. A. 
VCAM-1 mRNA and protein levels were determined in HUVEC under different stimulus for 24 h: 
normoxia (Nx), hypoxia 0.5 % O2 (Hp), DMOG (1 mM) or SM7368 at 20 µM (SM) alone or in combination 
with TNFα (20 ng/ml). Gene expression was represented as fold change over the levels of cells in normoxic 
conditions and controlled with β-Actin as the housekeeping gene. Statistical analysis was made using one-
way ANOVA test followed by Bonferroni’s post hoc test, the values represent the average ± SEM (n=5) 
experiments, **P<0.01, ***P<0.001 and ****P<0.0001 were considered significant. A representative 
Western blot is shown (n=5). B. VCAM-1 mRNA and protein levels were determined in HUVEC untreated 
or transfected with a scrambled siRNA (Scr), or siRNAs specific for VHL in the presence or absence of 
TNFα (20 ng/ml). Gene expression was represented as fold change over the levels of cells untreated and 
controlled with β-Actin gene expression levels. Statistical analysis was made using two-ways ANOVA test 
followed by Bonferroni’s post hoc test. The values represent the average ± SEM (n=4) experiments, 
***P<0.001 and ****P<0.0001 were considered significant. A representative Western blot, n=4 is shown. 
As a loading control α-Tubulin levels were analyzed. 
 
2.07 VHL loss or hypoxia diminish monocytic cell adhesion to ccRCC cells.  
It is well known that VCAM-1 through its binding to the integrins α4β1 and α4β7 mediates 
binding of circulating monocytes and lymphocytes to the endothelium [219]. Similarly, VCAM-
1 expression on the surface of tumor cells mediates interaction of several cell types of the 
hematopoietic lineage that express α4 integrin [294]. To study whether VCAM-1 decrease in 
ccRCC cells played any functional role in the biology of these tumor cells, we analyzed their 
capacity to mediate monocytic cell adhesion. To this aim we used two monocytic cell lines labeled 
with fluorescent markers. We incubated them with our ccRCC cell lines and let them interact for 
20 min and afterwards we quantified cell-cell adhesion by counting fluorescent cells. Our results 
proved that monocytes binding to ccRCC cells was VHL-dependent since adhesion to VHL 
negative cells was significantly lower compared to the adhesion to VHL expressing cells (Figure 
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45A, B). Similarly, hypoxia significantly decreased monocytes binding to ccRCC cells (Figure 
45C). 
 
Figure 45: Effects of VHL loss and 
hypoxia on monocytic cell adhesion to 
ccRCC cells. 786-O-VHL or 786-pRv 
cells were grown at confluence in a 24-
multiwell plate and cultured under 
normoxic conditions. Then THP1 A. or 
U937 B. monocytic cell lines (60x103 
cells/well) previously labelled with 10 
mM calcein-AM (green) were added. Cell 
adhesion was performed for 20 min at 
37ºC and afterwards attached fluorescent 
cells were counted under the microscope. 
Data is represented as number of cells ± 
SEM (n=5). Ten random fields were 
analyzed per condition and two-tailed 
Student’s t-test was performed, *P<0.05, 
was considered significant. 
Representative images of attached THP1 
or U937 monocytic cell (green) are 
shown. (C) U937-calcein-AM labelled 
cell adhesion on 786-O-VHL or 786-pRv 
cells previously cultured under normoxia 
(Nx) or hypoxia  0.5 % O2 (Hp) for 24 h. 
Cell adhesion was performed for 20 min 
at 37ºC and afterwards fluorescent cells 
were counted under the microscope. Data 
is represented as number of cells ± SEM 
(n=5), ten random fields were analyzed 
per condition. Statistical analysis was 
made using two-way ANOVA test 
followed by Bonferroni’s post hoc test, 
***P<0.001, ****P<0.0001 was 
considered significant, ns (not 
significant). Scale bars 50 nm 
 
 
 
2.08 Monocytic-ccRCC cell adhesion through VCAM-1-α4β1 interaction promotes a cytotoxic immune 
response. 
 
Given that VHL loss or hypoxia regulated the adhesion of monocytic cells to ccRCC, we asked 
whether this was mediated by VCAM-1 interaction with its cognate receptor the integrin α4β1 
(VLA4). To this aim we knocked down VCAM-1 expression in VHL positive cells and then tested 
ccRCC-monocytes cell adhesion. We observed that cell adhesion was significantly decreased 
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when VCAM-1 levels were decreased (Figures 46). Interestingly this adhesion was similar to that 
observed in VHL-negative cells, which might be explained by the fact that VCAM-1 levels after 
siRNA interference, and those in VHL negative cells were comparable (Figure 46).  
 
 
 
 
 
 
 
 
 
 
Figure 46: Role of VCAM-1 regulation in monocyte adhesion to ccRCC. A. Analysis of VCAM-1 
protein levels in 786-O-pRv or 786-O-VHL cells untreated, or transfected with a scrambled siRNA (Scr), 
or siRNAs specific for VCAM-1. α-Tubulin was used as a loading control. Western blot representative of 
three experiments is shown. B. U937-calcein-AM labelled cell adhesion on 786-O-pRv or 786-O-VHL 
cells untreated, or transfected with a scrambled siRNA (Scr), or siRNAs specific for VCAM-1. Cell 
adhesion was performed for 20 min at 37ºC and afterwards fluorescent cells were counted under the 
microscope. Data is represented as number of cells ± SEM (n=5), and ten random fields were analyzed per 
condition. Statistical analysis was made using one-way ANOVA test followed by Bonferroni’s post hoc 
test, ***P<0.001 was considered significant. 
 
 
More importantly, monocytic cell adhesion to VHL positive cells was also inhibited in the 
presence of VCAM-1 receptor blocking antibodies, like those blocking the α4 or β1 subunits of 
the integrin α4β1, while no effects were observed with an αL blocking antibody as a control 
(Figure 47). However, cell adhesion to VHL negative cells was not further decreased in the 
presence of these blocking antibodies (Figure 47). These results demonstrate that ccRCC cells are 
able to elicit immune cell binding and this is specifically mediated by VCAM-1 interaction with 
the integrin α4β1.  
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Figure 47: Role of VCAM-1/α4β1 interaction in monocyte adhesion to ccRCC. U937-calcein-AM 
labelled adhesion experiment on 786-O-pRv or 786-O-VHL untreated (Control) or treated with 10 µg/mL 
of blocking antibodies against β1, α4, or αL integrin subunits. Cell adhesion was performed for 20 min at 
37ºC and afterwards fluorescent cells were counted under the microscope. Data is represented as number 
of cells ± SEM (n=4), ten random fields were analyzed per condition. Statistical analysis was made using 
two-way ANOVA test followed by Bonferroni’s post hoc test, **P<0.01 significant, ns (not significant).  
 
U937 cells have been widely used as a model to investigate a variety of biological processes 
related to monocyte and macrophage function. Our results indicating that VCAM-1 expression 
on the surface of ccRCC cells allowed interaction with monocytic cells made conceivable that 
this interaction might trigger an immune response against tumor cells. Therefore, we assessed 
cytotoxicity assays in co-cultures of ccRCC with human monocytic cells activated towards a M1 
phenotype. We observed that loss of VHL conferred a cell advantage against the cytotoxic effects 
of activated monocytic cells since it reduced ccRCC death (Figure 48). These results indicate that 
VCAM-1 decrease in tumor cells lacking VHL or in hypoxia adversely affect the antitumor 
immune response.  
Figure 48: Effects of VHL loss in monocytic cell-
mediated cytotoxicity against ccRCC cells. 786-O-
pRv or 786-O-VHL target cells were seeded into 16-
well sensor plates and activated human monocytes 
treated with INF-γ and LPS were directly added into 
wells at a 60/1 ratio monocytes/ccRCCs. Cell 
survival measurements were automatically collected 
every 5 min by the by the analyzer RT-CES system 
(xCELLigence System, Roche) for up to 96 h. 
Cellular index results were expressed as cell survival 
percentage at 96 h. Data are representative of three 
different experiments. Statistical analysis between 
different conditions was made using two-way 
ANOVA test followed by Bonferroni’s post hoc test, 
***P< 0.001 was considered significant.  
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2.09 Analysis of VCAM-1 levels in human ccRCC.  
To address a possible clinical value of our data we analyzed VCAM-1 expression levels in 
nephrectomy samples from patients with ccRCC. We analyzed a cohort with a total of 127 tumor 
samples that were divided into two groups according to the type of VHL mutation. One group 
included missense mutations and the other one non-missense mutations, these including nonsense, 
insertions, deletions and methylations. In these two groups, we analyzed the association between 
VCAM-1 expression levels and several clinicopathologic variables.  
 
Table 6: Effects of VHL mutations on VCAM-1 expression levels and its association with 
clinicopathologic characteristics in human ccRCCs. 
 
VHL 
alteration 
N VCAM-
1 levels 
P 
Clinicopathologic 
characteristics 
 N VCAM-
1 levels 
p* 
 
         
Missense 32 2.622 0.739 Tumor stage I+II 12 2.943 0.613 
     III+IV 20 1.933  
         
    Tumor grade 1+2 22 2.943 0.223 
     3+4 10 1.484  
         
    Tumor size ≤7 19 3.042 0.173 
     7.1≥ 13 1.775  
         
    Microvascular invasion neg pos 
19 
13 
2.846 
1.775 0.863 
         
    Symptom presentation neg 12 3.577 0.018 
     pos 20 1.225  
         
         
Non-missense 95 2.099  Tumor stage I+II 55 2.481 0.01 
     III+IV 40 1.562  
         
    Tumor grade 1+2 70 2.309 0.001 
     3+4 25 1.336  
         
    Tumor size ≤7 77 2.250 0.118 
     7.1≥ 18 1.492  
         
    Microvascular invasion neg pos 
57 
38 
2.524 
1.650 0.009 
         
    Symptom presentation neg 57 2.481 0.004 
     pos 38 1.588  
         
*Mann-Whitney U test 
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Our results indicated that VCAM-1 levels were higher in samples included in the group of VHL 
missense mutations compared with non-missense mutations, although this difference did not 
reach statistical significance. However, we observed a negative association between VCAM-1 
levels and ccRCC stage and microvascular invasion that was statistically significant in the group 
with non-missense mutations (p≤0.05 Mann-Whitney U test, Table 6). Overall, our results point 
out the clinical value of VCAM-1 levels as a marker of ccRCC progression. In addition, they also 
point to effects on the regulation of VCAM-1 that appear to be dependent on the type of VHL 
mutation. 
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DISCUSSION 
In this thesis, we have addressed the role of hypoxia in physiopathology, and in particular we 
have treated two different topics; pulmonary arterial hypertension and clear cell renal cell 
carcinoma. Since these topics were presented as well in two experimental sections of results, we 
decided to discuss them separately to develop a deeper argumentation of each pathology. 
Nonetheless, we have included a final remark section trying to stablish a relationship between 
these two diseases. Both are related with hypoxia and with some of its molecular pathways. 
Hypoxia activates the molecular acute mechanism to adapt the organism, which is essential in 
acute onset, but harmful in prolonged or chronic hypoxia. In the case of PAH prolonged exposure 
to low levels of oxygen is the cause of the disease, while in the case of clear cell renal cell 
carcinoma, local hypoxia is a consequence of an uncontrolled proliferation, characteristic of 
cancer growth, and the stabilization of HIF due to the loss of VHL. Although both pathologies 
have converging points, the molecular mechanisms are different.  
 
1. TSP1, THE NEW HYPOXIO-SPONDIN AND ITS EMERGING ROLE IN PAH.  
Oxygen is essential for mammalian life and cells are well designed to rapidly alter gene 
expression profiles in response to changes in the partial pressure of oxygen. Hypoxia activates 
cellular sensing mechanisms focused on restoring oxygen to the hypoxic regions and maintain 
cell viability. Previous studies from human and animal models point to HIF1α and HIF2α as 
important regulators in pulmonary vascular responses to both acute and chronic hypoxia [160-
163, 295]. However, results from human subjects and mice models highlight the relevance of 
HIF2α in PAH [164]. Individuals with Chuvash polycythemia, which is caused by a mutation in 
VHL, are found to develop PAH [296]. In addition, pulmonary HIF2α activity was found to be 
increased in a murine model of Chuvash polycythemia, whereas loss of one copy of the HIF2α 
gene was associated with less pulmonary hypertension in these animals [165]. Not unexpectedly, 
HIF2α gain-of-function mutations are associated with pulmonary arterial hypertension [162, 164, 
297]. Moreover, EPO, a downstream target of HIF2α [298], is increased in the peripheral blood 
and endothelial cells from explanted lungs of end-stage PAH patients [299, 300]. In hPASMC 
hypoxia, via HIF2α, increases expression of the transcription factor forkhead box M1 (FoxM1) 
to promote cell proliferation [301], and the downstream gene target octamer-binding transcription 
factor 4 (Oct4) [302].  
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We now find that HIF2α induces TSP1 levels in hypoxic murine lungs. Furthermore, in animals 
lacking HIF2α, hypoxic upregulation of pulmonary TSP1 was completely abrogated. In addition, 
TSP1 induction in vhl-/- mice, that have constitutive HIF activity and mimic chronic hypoxia, was 
only reverted in the absence of HIF2α, but not when HIF1α was eliminated, suggesting that HIF2α 
is necessary for hypoxic-mediated pulmonary induction of TSP1. Moreover, we have seen that 
the arterial remodeling phenotype of vhl-/- was partially decreased in the vhl-/-/hif2α-/- double null 
mice (unpublished data). Likewise, in both human and murine pulmonary vascular and non-
vascular cells hypoxia stimulated an increase in TSP1 mRNA and protein levels. This was due to 
a transcriptional mechanism mediated by HIF2α-binding to hypoxia-response elements close to 
the tsp1 promoter.  
Curiously, in mPASMC, hypoxic challenge resulted in a modest and non-significant increase in 
TSP1 transcript. Although the reasons for this remain to be determined, it is possible that cell 
viability was adversely altered under the serum restricted conditions of the experiment. However, 
we cannot exclude that other HIF-independent events could also affect TSP1 protein levels in 
hypoxic PASMC. Finally, preliminary results in a cohort of human PAH and non-PAH samples 
suggests that both HIF1α and HIF2α might be involved in the regulation of TSP1 in human lungs 
in the pulmonary vasculature. However, a more extensive investigation in human PAH will be 
required to confirm these initial findings.  
Migration of PA fibroblasts and PASMC contribute to PA remodeling and luminal narrowing in 
PAH [303]. Previous studies from our group found tsp1-/- systemic arterial smooth muscle cells 
deficient in platelet-derived growth factor-driven migration compared to WT cells [304]. 
Consistent with this, we observed that under hypoxia mFIB and mPASMC from tsp1-/- mice had 
decreased migration compared with cells from WT mice. These in vitro data predict an effect in 
vessel remodeling in hypoxic lungs, in keeping with our previous results demonstrating decreased 
PA remodeling in tsp1-/- mice following chronic hypoxia [169]. In cells from TSP1 wild type mice 
hypoxia-mediated increase in pulmonary TSP1 likely stimulated mFIB and mPASMC migration, 
in part, through decreasing cell-matrix adhesion. In contrast, the expression of focal adhesion 
(FA) contacts in hypoxic tsp1-/- mFIB and mPASMC was not significantly affected. These results 
support previous findings from Dr. Murphy Ulrich laboratory regarding the role of TSP1 in the 
regulation of FA. In their studies, they observe that TSP1 activates focal adhesion kinase (FAK), 
and this mediates the activation of PI3K and ERK, which culminate with the inactivation of the 
small GTPase protein Rho A and FA disassembly [269]. The pathogenesis of PAH also involves 
endothelial cell dysfunction that plays an integral role in mediating the structural changes in the 
pulmonary vasculature. Our new findings herein demonstrate that hypoxia-mediated induction of 
TSP1 levels contributed to increase endothelial permeability, this mediated in part by changes in 
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cell-cell adhesion. This in fact may facilitate PASMC migration through the endothelial barrier 
and may be an initial cause of endothelial dysfunction, which in turn might contribute to vessel 
remodeling during PAH. In addition, we also showed that hypoxia-mediated induction of TSP1 
may induce human adventitial fibroblast differentiation into cells with SMC-like phenotype 
expressing SMA decorated F-Actin filaments. These cells could also contribute to the hyperplasia 
of the tunica media. This in vitro differentiation was reverted in the presence of TSP1 and TGF-𝛽 inhibitors, indicating that TSP1 through the activation of TGF-𝛽 can be involved in this process. 
These results give new insights into the molecular mechanisms that regulate TSP1 in hypoxic 
lungs. They also reveal the possible role of hypoxia in the control of cellular functions relevant 
to PAH, but most of our studies have been performed in cultured cells and we believe that it is 
crucial to illuminate PAH events at the organ scale. We performed passive CLARITY in mice 
lungs to create a pulmonary transparent structure, which allowed us to do immunofluorescence 
and take high-resolution 3D images without disrupting the organ. Although the technique still 
needs to be improved, we obtained some considerable achievements. Staining with SMA was 
observed in big arteries and bronchus, although small arteries labeling still needs further 
improvements. Regarding TSP1 immunofluorescences on clarified lungs exposed to Hp/Sugen 
for 3 weeks we observed a big increment of TSP1 protein levels that appeared like aggregates in 
the parenchyma, with a higher density in the peripheral area of the lung. This is still puzzeling to 
us and raised more questions than answers to our research project. We do not know exactly the 
origin of TSP1 and which cells are contributing to its increase under hypoxia. However, our 
hypothesis is that it could be an additive increment from cells in the PA, cells from the 
parenchyma, or it could also be released from blood cells, circulating TSP1 released from the 𝛼-
granules in platelets. In this respect Kaiser et al 2016 [172] showed that patients with chronic 
thromboembolic PH (CTEPH) have a 20-fold increase on TSP-1 circulating concentration 
compared to healthy controls and that this TSP1 increment correlates with bad hemodynamic 
parameters as PA pressure mean (PAPm) and systolic PA pressure (PAPsys). In addition, they 
show a correlation of TSP1 levels with patient survival in that high levels of TSP1 are associated 
with an increase in mortality. Due the role of TSP1 in platelet aggregation [305, 306] and the 
results from Kaiser et al [172] we believe that the aggregates we observed in our hypoxic lungs 
are little thrombus created by a high increase of TSP1. Therefore, TSP1 secreted from platelets 
may have a new and unsuspected function during PAH. This is interesting and further 
experimental work needs to be done to confirm our hypothesis.  
Together these data provide genetic evidence that TSP1 drives hypoxic pulmonary vascular 
remodeling. These findings also provide possible mechanistic insight into the previously reported 
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finding that HIFs stimulate pulmonary fibroblast migration [307], which based on our results 
herein, is mediated to some degree through the induction of TSP1.  
At a functional level, we found that endothelial-dependent vasodilation elicited by ACh was 
impaired in hypoxic PA from WT mice. In contrast, hypoxic tsp1-/- PA retained sensitivity to Ach, 
indicating a decrease in NO release which supports previously published results from our group 
in collaboration with Dr Isenberg´s group (University of Pittsburgh)[169, 280]. In addition, 
arterial contraction and the increase in intracellular calcium induced by the Kv1.5 channel 
inhibitor DPO1 were markedly decreased in hypoxic versus normoxic WT PA whereas tsp1-/- PA 
were resistant to these DPO1 effects. The reduced contraction in response to DPO1 in hypoxic 
WT PAs is consistent with the downregulation of Kv1.5 mRNA levels and with the decreased 
accumulation of intracellular calcium observed in mPASMC. These results are in agreement with 
studies showing reduced Kv1.5 channel activity and expression in cultured mPASMC [308-310] 
and intact animals [311, 312] exposed to chronic hypoxia. Downregulation of Kv1.5 and other 
oxygen-sensitive Kv channels is associated with loss of acute hypoxia-mediated pulmonary 
vasoconstriction [312, 313]. As Kv1.5 channel expression is preserved in tsp1-/- mice, it is 
expected that hypoxic pulmonary vasoconstriction would be preserved rather than lost when these 
mice are exposed to chronic hypoxia. However, the mechanisms underlying the preservation of 
Kv1.5 channel activity in isolated PA from tsp1-/- mice remain unknown. Of some possible 
importance in this regard, it was previously reported that endothelin receptor protein levels were 
downregulated in lungs from tsp1-/- compared to WT mice [280]. As ET-1 is known to inhibit 
Kv1.5 channels [314, 315], this raises the possibility that the TSP1 effects on Kv channel-
mediated contraction in hypoxic PA could be mediated through ET-1. We have recently unraveled 
in collaboration with Dr Isenberg´s group a new mechanism of the TSP1/CD47 axis in PAH. 
TSP1 through binding to its CD47 membrane receptor inhibits c-myc activity increasing the 
synthesis of ET-1, one of the most relevant hallmarks of PAH [316]. 
Alternatively, the resistance of tsp1-/- PA to hypoxia may be due to effects on other signaling 
moieties including ROS that are increased in hypoxia [317] and promote vasoconstriction. 
Previous reports indicate that TSP1 can directly activate NADPH oxidases in aortic vascular 
smooth muscle cells [318] and renal tubular epithelial cells [319] to increase superoxide 
production. In addition, our previous results obtained in Bauer et al 2012 [169] suggest a 
mechanism by which TSP1 signaling via CD47 could influence PAH by promoting an increase 
in ROS due to decoupling of endothelial nitric oxide synthase (eNOS) in PAEC. However, it 
remains to be seen if TSP1 directly stimulates enzymatic ROS production in the pulmonary 
vasculature.  
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The present results show that hypoxia, in a HIF2α-dependent manner, elicits an increase on TSP1 
levels in tissues and PA cells mediating structural changes in the pulmonary vasculature 
(summarized in Figure 49). Together these new findings suggest multiple mechanisms through 
which TSP1 may promote PAH. While its original identification as a thrombin-sensitive protein 
coined its name “thrombospondin” [177], its induction by hypoxia and its role in PAH may, in 
fact, lead us to think of TSP1 rather as the new “hypoxio-spondin”, as suggested by Shimoda and 
Kuebler [320]. As TSP1 has been found to be increased in several pulmonary diseases associated 
with excessive fibrosis [321-323], asthma [324] and COPD [325] our present findings likely have 
implications beyond PAH.  
 
Figure 49: Hypoxia, in a HIF2α-dependent manner, elicits an increase on TSP1 levels in PA cells 
mediating changes in their cellular behavior. Graphical abstract showing HIF2α binding to tsp1 HREs 
and effects of TSP1 on PA cells (migration, endothelial dysfunction, myodifferentiation and contraction). 
 
2. REGULATION OF VCAM-1 LEVELS THROUGH A VHL-PHD-NFΚB-DEPENDENT PATHWAY 
AND ITS ROLE IN THE IMMUNE RESPONSE AGAINST CLEAR-CELL RENAL CELL CARCINOMA. 
Clear cell renal cell carcinoma is one of the most abundant cancers in the world [198]. Remarkably, 
50–80% of sporadic renal cell carcinomas (RCC) and the most frequent form with clear cell 
histologic feature (ccRCC) present inactivating mutations or epigenetic silencing of VHL [203]. 
Although the role of VHL in the regulation of HIF prove to be important for tumor growth, other 
VHL functions independent of HIF have been reported and help to explain why loss of VHL leads 
to renal cancer [207]. Previous studies report the relevance of VHL expression on VCAM-1 levels 
in renal carcinoma [326, 327] and other studies correlate higher levels of VCAM-1 expression in 
ccRCC with a better prognosis [209-211], however the mechanism underneath VCAM-1 
regulation in these tumors remains unknown.  
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Our studies demonstrate that VHL loss or hypoxia down-regulate VCAM-1 mRNA and protein 
levels in ccRCC cells. This regulation was at the transcriptional level but independent of HIF. 
Interestingly ccRCC cells treatment with TNF-α reverted VCAM-1 decrease in VHL positive 
cells under hypoxia, although this was not reproduced in VHL negative cells. In agreement with 
these results previous findings demonstrate a VHL-dependent sensitization of RCC cells to 
TNFα-mediated effects [328]. This regulation does not appear to be exclusive to tumor cells, since 
TNF-α-induced expression of VCAM-1 in HUVEC was significantly decreased under hypoxia, 
or when treated with PHD or NF-κB inhibitors, as well as in cells treated with VHL siRNA. This 
is of especial relevance in the setting of tumor migration and immune cell trafficking. 
Although VHL most accepted function is as an ubiquitin ligase that targets various proteins for 
degradation by the proteasome, it has also been observed that VHL has an opposite role promoting 
protein half-life of several proteins such as BIMEL [77], p53 [78] and Jade-1 [79]. Previous 
results demonstrate a constitutive activation of the NF-κB pathway in RCC cell lines. On the other 
hand, VHL expression abolishes the canonical NF-κB pathway and the induction of anti-apoptotic 
genes in those cells [92-94]. Furthermore, other authors have shown that PHD2 controls TNF-α 
effects by positively regulating NF-κB signaling [103], and PHD3 serves as a co-activator of NF-
κB signaling activity [104]. Our results demonstrate that both VHL and PHD activity are required 
to maintain VCAM-1 levels in ccRCC cells and they are essential for TNFα-mediated induction 
of VCAM-1 through a NF-κB non-canonical pathway. These results are relevant considering the 
results published by Cummins et al. [95] in which they show that kinases of the NF-κB signaling 
pathway, IKKα and IKKβ, contain the LXXLAP motif for proline hydroxylation. These authors 
demonstrate that IKKs co-immunoprecipitate with PHD1 and with VHL. Interestingly, this 
interaction does not result in ubiquitination or proteasomal degradation of IKKs. Although we 
were unable to demonstrate a direct interaction of VHL with IKKs in ccRCC cell lines, probably 
due to the lability of this interaction, our results clearly prove that in the absence of VHL or in 
hypoxia the non-canonical NF-κB pathway is affected and this contributes to decrease VCAM-1 
levels. 
NF-kB non-canonical pathway requires IKKa-dependent NF-kB2 (p100) processing in the 
proteasome to generate the binding subunit p52. This subunit is then associated to the 
transcriptional activator Rel B, enters the nucleus and binds to DNA-NF-kB binding sites in 
certain NF-kB-responsive genes [329-331]. In our ccRCC cell lines we observed that IKKa and 
the upstream activator NIK [332] were decreased in the absence of VHL. Furthermore, Rel B and 
p52 were notably decreased under hypoxia or in the absence of VHL, while no changes in the 
canonic binding subunit p65 were observed. The possibility exists that PHD-mediated 
hydroxylation of the non-canonical activator IKKa promotes VHL binding or an intermediate 
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protein that is also regulated by VHL. This interaction activates the non-canonical pathway while 
its interaction with IKKβ represses the canonical pathway. Alternatively, an upstream regulation 
of the non-canonical pathway might occur after direct hydroxylation of NIK by PHDs. In this 
respect, NIK contains an LXXXLAP sequence that is similar to the LXXLAP consensus 
hydroxylation sequence present in IKKs [95]. Although these results demonstrated that the non-
canonical pathway was involved in VCAM-1 regulation in these cells, we cannot discard that the 
canonical NF-κB pathway might also contribute.  
NF-κB signaling pathways have a diverse spectrum of effects and the NF-κB canonical pathway 
represents only a fraction of the whole range of genes that are regulated by this family of 
transcription factors. Despite it is well established that canonical NF-κB regulates VCAM-1 in 
many different cell types [236], the binding of non-canonical dimers to the VCAM-1 NF-kB 
described binding sites is highly probable due to the high similarity among these sequences. Our 
model proposes that VHL-PHD signaling promotes NF-κB non-canonical pathway that increases 
VCAM-1 levels while downregulating the NF-κB canonical pathway (Figure 50). Future studies 
will be required to clarify whether canonical and non-canonical NF-κB pathways are 
interconnected or differentially activated in ccRCCs contributing to tumor growth and 
progression. Although the two pathways usually cooperate in their biological functions, negative 
interplays have also been identified. The positive and negative interplays between the two NF-κB 
pathways may serve to modulate the kinetics and magnitude of expression of NFκB target genes.  
The biological roles of the non-canonical NF-κB pathway have been extensively studied [333-
335], however how this pathway functions in specific cell types is still unclear. VCAM-1 has 
been generally correlated with activated endothelium; although its expression has also been 
detected in tumor models in which the function attributed to VCAM-1 depends on the type of 
tumor. Thus, recent studies in breast cancer and gastric carcinoma have shown that increased 
expression of VCAM-1 in these tumors favors metastasis to organs such as lung and bone [336, 
337]. Conversely, other studies have highlighted the important role of VCAM-1 in the 
development of kidney tumors, in which an inverse correlation between the expression of VCAM-
1 and tumor malignancy has been observed [209-211]. In agreement with these results we have 
shown that VCAM-1 expression levels were decreased in a cohort of human ccRCC carrying 
VHL non-missense mutations compared to those with missense mutations. In addition, a negative 
correlation between VCAM-1 levels and ccRCC stage and microvascular invasion was only 
statistically significant in the group with non-missense mutations. These results suggest the 
existence of differential effects on VCAM-1 regulation and functions that might depend on the 
type of mutation affecting VHL. This is also supported by our in vitro results in which we 
observed that TNF-α-mediated regulation of VCAM-1 levels was differentially affected in 
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various VHL mutants. In addition, our results demonstrated that VCAM-1 expression in VHL 
positive ccRCC cell promotes adhesion to monocytic cells through its interaction with the integrin 
α4β1 and elicits an M1 cytotoxic response. Conversely, VHL loss or hypoxia disrupts this 
interaction probably due to the decrease in VCAM-1 levels.  
Taken together these findings reveal pathways that may be critical in ccRCC tumorigenicity, and 
identify novel candidates that could serve as targets for future therapeutic intervention or as 
diagnostic/prognostic biomarkers for patients with advanced ccRCC. In addition, the findings 
described herein may help to understand how VHL acts as a gatekeeper gene in the kidney and 
provide an insight into the existence of VHL-regulated functions through HIF-independent 
mechanisms. A better understanding of the molecular mechanisms that allow tumors to escape 
immune response will be a great benefit on the development of strategies for cancer treatment 
 
 
Figure 50: Proposed molecular model of VCAM-1 regulation in ccRCC-VHL expressing cells. IKKα 
and IKKβ hydroxylation by active PHDs in normoxic conditions allows VHL binding to IKKs. VHL-
dependent regulation of IKKα promotes the non-canonical pathway while regulation of IKKβ represses the 
canonical pathway. Alternatively, an upstream regulation of the non-canonical pathway might occur after 
PHD direct hydroxylation of NIK. These events regulate transcriptional effectors of the non-canonical 
pathway (p52-RelB) that ultimately lead to the upregulation of VCAM-1 in Nx. VCAM-1 increase in the 
ccRCC cell membrane promotes binding to monocytes VLA-4 (α4β1 integrin) and activates their 
antitumoral effects. In the absence of VHL or in hypoxia this pathway is nonfunctional and VCAM-1 
transcriptional induction is repressed. Black arrows indicate previously published data. Grey arrows 
indicate the proposed model based on results from this thesis.  
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3. FINAL REMARKS. 
In this thesis work we have addressed the role of hypoxia in physiopathology, in particular in lung 
disease such as PAH, and in ccRCC. We have shown how low oxygen is the cause of a 
pathological phenotype in hypoxic PAH, leading to processes that are orchestrated by HIF2α. 
Under hypoxic condition HIF2𝛼 is stabilized and upregulates the expression of tsp1. In a chronic 
setting, this matricellular protein, far from its homeostatic role becomes a great destabilizer 
triggering some important PAH events. 
In ccRCC we have a very different scenario; conversely to what we observed in our PAH model, 
in which the canonical pathway in hypoxia, after VHL loss triggered the induction of TSP1 in a 
HIF-dependent manner, in our ccRCC cell lines the loss of VHL or the inactivation of PHDs 
under hypoxia repressed the induction of VCAM-1 through HIF-independent mechanisms. 
Interestingly, in this case VHL and PHDs functions do not involve ubiquitination and proteasome 
degradation. In fact, the presence of VHL and activated PHDs seem to have a protective role 
increasing activity of the non-canonic NF-κB pathway. Surprisingly, these effects are probably 
not unique to this tumor model, as demonstrated in our experiments with HUVEC, which share 
the same regulation of VCAM-1 observed in tumor cells. This suggests that VHL is crucial for 
NF-κB pathway beyond cancer, but this is especially relevant in the setting of immune cell 
trafficking and tumor migration. 
Overall, we have found two molecular mechanisms affected by hypoxia in two pathologic 
contexts in which VHL plays a pivotal role together with PHDs. These results are relevant in that 
they help to understand the mechanisms behind disease and will benefit the development of new 
therapies.  
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CONCLUSIONS  
The findings presented herein support the following conclusions, which have been classified in 
two sections:  
TSP1, the new “hypoxio-spondin” and its emerging role in PAH. 
1. HIF2𝛼 regulates TSP1 induction under hypoxia in lungs, through its binding to HREs in 
the proximal promoter region of tsp1 both in human and mouse. 
2. Hypoxic-induced TSP1 in mouse PASMC and pulmonary fibroblasts increases cell 
migration through focal adhesion disassembly, and in human PAEC promotes 
disassembly of cell-cell mediated tight junctions and increases endothelial permeability. 
3. Hypoxic-induced TSP1 in human PAFIB leads to fibroblast differentiation into a SMC-
like phenotype increasing the number of SMA-decorated actin filaments through a 
process dependent of TFG-β. 
4. Hypoxic-induced TSP1 decreases vascular relaxation of PASMC, in part mediated by a 
reduction in the levels of Kv1.5 channel. 
5. The increase of TSP1 in pulmonary arteries of patients with PAH versus healthy controls 
could be considered as a diagnostic marker of the pathology as well as a new target for 
the development of new therapeutic strategies in PAH. 
Regulation of VCAM-1 levels through a VHL-PHD-NFκB-dependent pathway and its role 
in the immune response against clear-cell renal cell carcinoma. 
6. VHL loss, hypoxia and PHD inhibition or silencing inhibit VCAM-1 transcription in 
ccRCC cell lines in a HIF-independent manner. 
7. VCAM-1 regulation after VHL loss, hypoxia and PHD inhibition is mediated by a 
noncanonic NF-kB pathway. 
8. VCAM-1 decreased expression in ccRCC membrane decreases monocyte binding 
through its receptor, the α4β1 integrin. 
9. Monocytic-ccRCC cell adhesion through VCAM-1-α4β1 interaction promotes an 
immune response against tumor cells. 
10. Human ccRCC carrying non-missense mutations of VHL express lower levels of VCAM-
1 compared to those with missense mutations. Moreover, a negative correlation between 
VCAM-1 levels and ccRCC stage and microvascular invasion was only statistically 
significant in the group with non-missense mutations. 
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CONLCUSIONES 
 
Los hallazgos presentados en esta tesis apoyan las siguientes conclusiones, que se han clasificado 
en dos secciones: 
TSP1, la nueva “hipoxia-espondina” y su papel emergente en la HAP. 
1. HIF2α regula la inducción de TSP1 en hipoxia en el pulmón mediante su unión a HREs 
en la región promotora proximal de TSP1 tanto en humano como en ratón. 
2. La inducción de TSP1 por hipoxia aumenta la migración de PASMC y fibroblastos de 
pulmón murinos a través del desensamblaje de adhesiones focales, y en PAEC humanas 
promueve el desensamblaje de adhesiones intercelulares estrechas aumentando así la 
permeabilidad endotelial. 
3. La inducción de TSP1 por hipoxia induce la diferenciación de PAFIB humanos a un 
fenotipo tipo SMC con un aumento en el número de filamentos de actina decorados con 
SMA a través de un proceso dependiente de TFG-β. 
4. La TSP1 inducida por hipoxia disminuye la relajación vascular de PASMC, en parte 
mediada por una reducción en los niveles del canal de potasio Kv1.5. 
5. El aumento de la TSP1 en arterias pulmonares de pacientes con HAP versus controles 
sanos podría ser considerados como marcador diagnóstico de la patología, así como una 
nueva diana para el desarrollo de nuevas estrategias terapéuticas en HAP.  
Regulación de los niveles de VCAM-1 a través de una vía VHL-PHD-NFκB-dependiente y 
su papel en la respuesta inmune contra carcinoma renal de célula clara. 
6. La pérdida de VHL, la hipoxia y la inhibición o silenciamiento de las PHDs inhiben la 
transcripción de VCAM-1 en líneas celulares de ccRCC de manera independiente de HIF. 
7. La regulación de VCAM-1 por VHL, hipoxia o inhibición de las PHDs está mediada por 
la vía no-canónica de NF-𝜅B. 
8. La expresión disminuida de VCAM-1 en la membrana de células ccRCC disminuye la 
unión de monocitos a través de su receptor, la integrina α4β1. 
9. La adhesión célula ccRCC-monocito mediante la interacción VCAM-1-α4β1 promueve 
una respuesta inmune anti-tumoral. 
10. El ccRCC humano con mutaciones sin sentido en vhl expresa niveles más bajos de 
VCAM-1 en comparación con aquellos con mutaciones con cambio de sentido. Además, 
se demuestra una correlación negativa entre los niveles de VCAM-1 y el estadio del 
ccRCC y la invasión microvascular que es estadísticamente significativa en el grupo con 
mutaciones sin sentido. 
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1.1 Supplementary information 
 
Supplementary Movie 1. From figure 29 (SMA staining in clarified mouse lungs). Video depict 
a 400 µm z-stack 3D reconstruction of adult (3 months) WT mouse lungs clarified by passive 
CLARITY and stained for α-SMA with Alexa 488 (green). Big PAs and main bronchus can be 
appreciated. Scale bar indicates the image size.  Movie was mounted at 12 fps. 
Supplementary Movie 2. From figure 30 (TSP1 staining in clarified mouse lungs under 
Hp/Sugen treatment). Visualization of TSP1 in adult (3 month) mouse lung of male WT exposed 
to hypoxia (10%) plus sugen 5416 (Hp+Su) for 3 weeks. Mice lung were clarified by passive 
CLARITY and stained with TSP1 with Alexa 488 (fire).  Video depict a 400 µm z-stack 3D 
reconstruction. Scale bars indicate image size in each frame. Movie was mounted at 12 fps 
Supplementary Movie 3. Visualization of SMA in adult (3 month) mouse lung of male WT 
exposed to hypoxia (10%) plus sugen 5416 (Hp+Su) Sor 3 weeks. Video depict a 400 µm z-stack 
3D reconstruction of adult (3 months). Lungs were clarified by passive CLARITY and stained 
for α-SMA with Alexa 488 (green). Big PAs and main bronchus can be appreciated. Scale bar 
indicates the image size.  Movie was mounted at 12 fps. 
Supplementary Movie 4.  CNN1 staining in clarified mouse lungs. Video depict a 400 µm z-
stack 3D reconstruction of adult (3 months) WT mouse lungs clarified by passive CLARITY and 
stained for CNN.1 with Alexa 488 (green). Main bronchus can be appreciated. Scale bar indicates 
the image size.  Movie was mounted at 12 fps. 
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